US20080113958A1 - Modulators of muscarinic receptors - Google Patents

Modulators of muscarinic receptors Download PDF

Info

Publication number
US20080113958A1
US20080113958A1 US11/894,092 US89409207A US2008113958A1 US 20080113958 A1 US20080113958 A1 US 20080113958A1 US 89409207 A US89409207 A US 89409207A US 2008113958 A1 US2008113958 A1 US 2008113958A1
Authority
US
United States
Prior art keywords
optionally substituted
independently
compound
heterocycloaliphatic
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/894,092
Other versions
US20100063021A9 (en
US7786107B2 (en
Inventor
Robert J. Davies
Jingwang Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US11/894,092 priority Critical patent/US7786107B2/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED reassignment VERTEX PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIES, ROBERT J., XU, JINWANG
Publication of US20080113958A1 publication Critical patent/US20080113958A1/en
Publication of US20100063021A9 publication Critical patent/US20100063021A9/en
Application granted granted Critical
Publication of US7786107B2 publication Critical patent/US7786107B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to modulators of muscarinic receptors.
  • the present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
  • the neurotransmitter acetylcholine binds to two types of cholinergic receptors: the ionotropic family of nicotinic receptors and the metabotropic family of muscarinic receptors.
  • Muscarinic receptors belong to the large superfamily of plasma membrane-bound G protein coupled receptors (GPCRs). To date, five subtypes of muscarinic receptors (M 1 -M 5 ) have been cloned and sequenced from a variety of species, and show a remarkably high degree of homology across species and receptor subtype.
  • M 1 -M 5 muscarinic receptors are predominantly expressed within the parasympathetic nervous system which exerts excitatory and inhibitory control over the central and peripheral tissues and participate in a number of physiologic functions, including heart rate, arousal, cognition, sensory processing, and motor control.
  • Muscarinic agonists such as muscarine and pilocarpine
  • antagonists such as atropine
  • atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, thereby making it difficult to assign specific functions to the individual receptors. See, e.g., DeLapp, N. et al., “Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System,” J. Med. Chem., 43(23), pp. 4333-4353 (2000); Hulme, E. C. et al., “Muscarinic Receptor Subtypes,” Ann. Rev. Pharmacol. Toxicol., 30, pp.
  • the Muscarinic family of receptors is the target of a large number of pharmacological agents used for various diseases, including leading drugs for COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors).
  • leading drugs for COPD leading drugs for COPD
  • asthma urinary incontinence
  • glaucoma glaucoma
  • Alzheimer's Alzheimer's
  • cholinergic drugs are limited by the lack of selectivity of these agents, with significant activation of the parasympathetic autonomous system and elevated incidence of adverse effects.
  • the molecular cloning of the muscarinic receptors and the identification of the physiological role of specific isoforms using knock-out mice, has recently delineated novel opportunities for selective muscarinic ligands, and has helped to define the selectivity profile that is required for enhanced efficacy and reduced side effects.
  • the present invention provides methods of modulating the activity of a muscarinic receptor (e.g., M 1 , M 2 , M 3 , M 4 , M 5 , or combinations thereof) using compounds of formula I:
  • R 1 , R 2 , X 1 , X 2 , X 3 , X 4 , m, n, and q are described below.
  • muscle receptor refers to one or more of the five receptor subtypes M 1 -M 5 .
  • modulating means increasing or decreasing, e.g. activity, by a measurable amount.
  • Compounds that modulate muscarinic activity by increasing the activity of the muscarinic receptors are called agonists.
  • Compounds that modulate muscarinic activity by decreasing the activity of the muscarinic receptors are called antagonists.
  • An agonist interacts with a muscarinic receptor to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • An antagonist interacts with a muscarinic receptor and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • a muscarinic receptor mediated disease refers both to treatments for diseases that are directly caused by muscarinic activities and alleviation of symptoms of diseases not directly caused by muscarinic activities.
  • diseases whose symptoms may be affected by muscarinic activity include, but are not limited to, CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, bradhycardia, gastric acid secretion, asthma, GI disturbances and wound healing.
  • ADHD Attention Deficit Hyperactivity Disorder
  • obesity Alzheimer's disease
  • various dementias such
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • aliphatic encompasses the terms alkyl, alkenyl, alkynyl, each of which being optionally substituted as set forth below.
  • an “alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms.
  • An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl.
  • An alkyl group can be substituted (i.e., optionally substituted) with one or more substituents such as halo, cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], heterocycloaliphatic [e.g., heterocycloalkyl or heterocycloalkenyl], aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl [e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl], nitro, cyano, amido [e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbon
  • substituted alkyls include carboxyalkyl (such as HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxyalkyl), cyanoalkyl, hydroxyalkyl, alkoxyalkyl, acylalkyl, aralkyl, (alkoxyaryl)alkyl, (sulfonylamino)alkyl (such as (alkyl-SO 2 -amino)alkyl), aminoalkyl, amidoalkyl, (cycloaliphatic)alkyl, or haloalkyl.
  • carboxyalkyl such as HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxyalkyl
  • cyanoalkyl hydroxyalkyl, alkoxyalkyl, acylalkyl, aralkyl, (alkoxyaryl)alkyl, (sulfonylamino)alkyl (such as (alky
  • an “alkenyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl.
  • An alkenyl group can be optionally substituted with one or more substituents such as halo, cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], heterocycloaliphatic [e.g., heterocycloalkyl or heterocycloalkenyl], aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl [e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl], nitro, cyano, amido [e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino alkylamin
  • substituted alkenyls include cyanoalkenyl, alkoxyalkenyl, acylalkenyl, hydroxyalkenyl, aralkenyl, (alkoxyaryl)alkenyl, (sulfonylamino)alkenyl (such as (alkyl-SO 2 -amino)alkenyl), aminoalkenyl, amidoalkenyl, (cycloaliphatic)alkenyl, or haloalkenyl.
  • an “alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond.
  • An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl.
  • An alkynyl group can be optionally substituted with one or more substituents such as aroyl, heteroaroyl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, sulfanyl [e.g., aliphaticsulfanyl or cycloaliphaticsulfanyl], sulfinyl [e.g., aliphaticsulfinyl or cycloaliphaticsulfinyl], sulfonyl [e.g., aliphatic-SO 2 —, aliphaticamino-SO 2 —, or cycloaliphatic-SO 2 —], amido [e.g., aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, cycloalkylaminocarbonyl
  • an “amido” encompasses both “aminocarbonyl” and “carbonylamino”. These terms when used alone or in connection with another group refers to an amido group such as —N(R X )—C(O)—R Y or —C(O)—N(R X ) 2 , when used terminally, and —C(O)—N(R X )— or —N(R X )—C(O)— when used internally, wherein R X and R Y are defined below.
  • amido groups include alkylamido (such as alkylcarbonylamino or alkylaminocarbonyl), (heterocycloaliphatic)amido, (heteroaralkyl)amido, (heteroaryl)amido, (heterocycloalkyl)alkylamido, arylamido, aralkylamido, (cycloalkyl)alkylamido, or cycloalkylamido.
  • alkylamido such as alkylcarbonylamino or alkylaminocarbonyl
  • heterocycloaliphatic such as alkylcarbonylamino or alkylaminocarbonyl
  • heteroaryl heteroaryl
  • an “amino” group refers to —NR X R Y wherein each of R X and R Y is independently hydrogen, aliphatic, cycloaliphatic, (cycloaliphatic)aliphatic, aryl, araliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, heteroaryl, carboxy, sulfanyl, sulfinyl, sulfonyl, (aliphatic)carbonyl, (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)carbonyl, arylcarbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, (heteroaryl)carbonyl, or (heteroaraliphatic)carbonyl, each of which being defined herein and being optionally substituted.
  • amino groups examples include alkylamino, dialkylamino, or arylamino.
  • amino When the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by —NR X —. R X has the same meaning as defined above.
  • an “aryl” group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl, naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); and tricyclic (e.g., fluorenyl tetrahydrofluorenyl, or tetrahydroanthracenyl, anthracenyl) ring systems in which the monocyclic ring system is aromatic or at least one of the rings in a bicyclic or tricyclic ring system is aromatic.
  • the bicyclic and tricyclic groups include benzofused 2-3 membered carbocyclic rings.
  • a benzofused group includes phenyl fused with two or more C 4-8 carbocyclic moieties.
  • An aryl is optionally substituted with one or more substituents including aliphatic [e.g., alkyl, alkenyl, or alkynyl]; cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocyclic ring of a benzofused bicyclic or tricyclic aryl); nitro; carb
  • Non-limiting examples of substituted aryls include haloaryl [e.g., mono-, di (such as p,m-dihaloaryl), and (trihalo)aryl]; (carboxy)aryl [e.g., (alkoxycarbonyl)aryl, ((aralkyl)carbonyloxy)aryl, and (alkoxycarbonyl)aryl]; (amido)aryl [e.g., (aminocarbonyl)aryl, (((alkylamino)alkyl)aminocarbonyl)aryl, (alkylcarbonyl)aminoaryl, (arylaminocarbonyl)aryl, and (((heteroaryl)amino)carbonyl)aryl]; aminoaryl [e.g., ((alkylsulfonyl)amino)aryl or ((dialkyl)amino)aryl]; (cyanoalkyl)aryl; (alk
  • an “araliphatic” such as an “aralkyl” group refers to an aliphatic group (e.g., a C 1-4 alkyl group) that is substituted with an aryl group. “Aliphatic,” “alkyl,” and “aryl” are defined herein. An example of an araliphatic such as an aralkyl group is benzyl.
  • an “aralkyl” group refers to an alkyl group (e.g., a C 1-4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” have been defined above. An example of an aralkyl group is benzyl.
  • An aralkyl is optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl, including carboxyalkyl, hydroxyalkyl, or haloalkyl such as trifluoromethyl], cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, amido [e.g., aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloal
  • a “bicyclic ring system” includes 8-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common).
  • Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic aryls, and bicyclic heteroaryls.
  • cycloaliphatic encompasses a “cycloalkyl” group and a “cycloalkenyl” group, each of which being optionally substituted as set forth below.
  • a “cycloalkyl” group refers to a saturated carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms.
  • Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2.]decyl, bicyclo[2.2.2]octyl, adamantyl, azacycloalkyl, or ((aminocarbonyl)cycloalkyl)cycloalkyl.
  • a “cycloalkenyl” group refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bonds.
  • Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl, bicyclo[2.2.2]octenyl, or bicyclo[3.3.1]nonenyl.
  • a cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl], cycloaliphatic, (cycloaliphatic) aliphatic, heterocycloaliphatic, (heterocycloaliphatic) aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido [e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbon
  • cyclic moiety includes cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been defined previously.
  • heterocycloaliphatic encompasses a heterocycloalkyl group and a heterocycloalkenyl group, each of which being optionally substituted as set forth below.
  • heterocycloalkyl refers to a 3-10 membered mono- or bicylic (fused or bridged) (e.g., 5- to 10-membered mono- or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof).
  • heterocycloalkyl group examples include piperidyl, piperazyl, tetrahydropyranyl, tetrahydrofuryl, 1,4-dioxolanyl, 1,4-dithianyl, 1,3-dioxolanyl, oxazolidyl, isoxazolidyl, morpholinyl, thiomorpholyl, octahydrobenzofuryl, octahydrochromenyl, octahydrothiochromenyl, octahydroindolyl, octahydropyrindinyl, decahydroquinolinyl, octahydrobenzo[b]thiopheneyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa
  • a monocyclic heterocycloalkyl group can be fused with a phenyl moiety such as tetrahydroisoquinoline.
  • a “heterocycloalkenyl” group refers to a mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom (e.g., N, O, or S).
  • Monocyclic and bicycloheteroaliphatics are numbered according to standard chemical nomenclature.
  • a heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl], cycloaliphatic, (cycloaliphatic)aliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido [e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic) aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbony
  • heteroaryl group refers to a monocyclic, bicyclic, or tricyclic ring system having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof) and in which the monocyclic ring system is aromatic or at least one of the rings in the bicyclic or tricyclic ring systems is aromatic.
  • a heteroaryl group includes a benzofused ring system having 2 to 3 rings.
  • a benzofused group includes benzo fused with one or two 4 to 8 membered heterocycloaliphatic moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl).
  • heterocycloaliphatic moieties e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl.
  • heteroaryl examples include azetidinyl, pyridyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl, cinnolyl, quinolyl, quinazolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo-1,2,5-thiadiazolyl, or
  • monocyclic heteroaryls include furyl, thiophenyl, 2H-pyrrolyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4-H-pranyl, pyridyl, pyridazyl, pyrimidyl, pyrazolyl, pyrazyl, or 1,3,5-triazyl.
  • Monocyclic heteroaryls are numbered according to standard chemical nomenclature.
  • bicyclic heteroaryls include indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, indolizyl, isoindolyl, indolyl, benzo[b]furyl, bexo[b]thiophenyl, indazolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl, quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, 1,8-naphthyridyl, or pteridyl.
  • Bicyclic heteroaryls are numbered according to standard chemical nomenclature.
  • a heteroaryl is optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl]; cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocyclic or heterocyclic ring of a bicyclic or tricyclic heteroaryl); carboxy; amido; acyl [e.g., aliphaticcarbonyl; (cycloaliphatic)carbonyl; ((cycloaliphatic)aliphatic)carbonyl; (araliphatic)carbonyl;
  • Non-limiting examples of substituted heteroaryls include (halo)heteroaryl [e.g., mono- and di-(halo)heteroaryl]; (carboxy)heteroaryl [e.g., (alkoxycarbonyl)heteroaryl]; cyanoheteroaryl; aminoheteroaryl [e.g., ((alkylsulfonyl)amino)heteroaryl and ((dialkyl)amino)heteroaryl]; (amido)heteroaryl [e.g., aminocarbonylheteroaryl, ((alkylcarbonyl)amino)heteroaryl, ((((alkyl)amino)alkyl)aminocarbonyl)heteroaryl, (((heteroaryl)amino)carbonyl)heteroaryl, ((heteroaryl)amino)carbonyl)heteroaryl, (
  • heteroaralkyl refers to an aliphatic group (e.g., a C 1-4 alkyl group) that is substituted with a heteroaryl group.
  • aliphatic group e.g., a C 1-4 alkyl group
  • heteroaryl e.g., a C 1-4 alkyl group
  • heteroaryl group refers to an alkyl group (e.g., a C 1-4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above.
  • a heteroaralkyl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloal
  • an “acyl” group refers to a formyl group or R X —C(O)— (such as alkyl-C(O)—, also referred to as “alkylcarbonyl”) where R X and “alkyl” have been defined previously.
  • Acetyl and pivaloyl are examples of acyl groups.
  • an “aroyl” or “heteroaroyl” refers to an aryl-C(O)— or a heteroaryl-C(O)—.
  • the aryl and heteroaryl portion of the aroyl or heteroaroyl is optionally substituted as previously defined.
  • alkoxy refers to an alkyl-O— group where “alkyl” has been defined previously.
  • a “carbamoyl” group refers to a group having the structure —O—CO—NR X R Y or —NR X —CO—O—R Z wherein R X and R Y have been defined above and R Z can be aliphatic, aryl, araliphatic, heterocycloaliphatic, heteroaryl, or heteroaraliphatic.
  • a “carboxy” group refers to —COOH, —COOR X , —OC(O)H, —OC(O)R X when used as a terminal group; or —OC(O)— or —C(O)O— when used as an internal group.
  • haloaliphatic refers to an aliphatic group substituted with 1-3 halogen.
  • haloalkyl includes the group —CF 3 .
  • mercapto refers to —SH.
  • a “sulfo” group refers to —SO 3 H or —SO 3 R X when used terminally or —S(O) 3 — when used internally.
  • a “sulfamide” group refers to the structure —NR X —S(O) 2 —NR Y R Z when used terminally and —NR X —S(O) 2 —NR Y — when used internally, wherein R X , R Y , and R Z have been defined above.
  • a “sulfonamide” group refers to the structure —S(O) 2 —NR X R Y or —NR X —S(O) 2 —R Z when used terminally; or —S(O) 2 —NR X — or —NR X —S(O) 2 — when used internally, wherein R X , R Y , and R Z are defined above.
  • sulfanyl group refers to —S—R X when used terminally and —S— when used internally, wherein R X has been defined above.
  • sulfanyls include aliphatic-S—, cycloaliphatic-S—, aryl-S—, or the like.
  • sulfinyl refers to —S(O)—R X when used terminally and —S(O)— when used internally, wherein R X has been defined above.
  • exemplary sulfinyl groups include aliphatic-S(O)—, aryl-S(O)—, (cycloaliphatic(aliphatic))-S(O)—, cycloalkyl-S(O)—, heterocycloaliphatic-S(O)—, heteroaryl-S(O)—, or the like.
  • a “sulfonyl” group refers to —S(O) 2 —R X when used terminally and —S(O) 2 — when used internally, wherein R X has been defined above.
  • Exemplary sulfonyl groups include aliphatic-S(O) 2 —, aryl-S(O) 2 —, (cycloaliphatic(aliphatic))-S(O) 2 —, cycloaliphatic-S(O) 2 —, heterocycloaliphatic-S(O) 2 —, heteroaryl-S(O) 2 —, (cycloaliphatic(amido(aliphatic)))-S(O) 2 — or the like.
  • a “sulfoxy” group refers to —O—SO—R X or —SO—O—R X , when used terminally and —O—S(O)— or —S(O)—O— when used internally, where R X has been defined above.
  • halogen or “halo” group refers to fluorine, chlorine, bromine or iodine.
  • alkoxycarbonyl which is encompassed by the term carboxy, used alone or in connection with another group refers to a group such as alkyl-O—C(O)—.
  • alkoxyalkyl refers to an alkyl group such as alkyl-O-alkyl-, wherein alkyl has been defined above.
  • a “carbonyl” refer to —C(O)—.
  • an “oxo” refers to ⁇ O.
  • aminoalkyl refers to the structure (R X ) 2 N-alkyl-.
  • cyanoalkyl refers to the structure (NC)-alkyl-.
  • urea refers to the structure —NR X —CO—NR Y R Z and a “thiourea” group refers to the structure —NR X —CS—NR Y R Z when used terminally and —NR X —CO—NR Y — or —NR X —CS—NR Y — when used internally, wherein R X , R Y , and R Z have been defined above.
  • guanidine refers to the structure —N ⁇ C(N(R X R Y ))N(R X R Y ) or —NR X —C( ⁇ NR X )NR X R Y wherein R X and R Y have been defined above.
  • amino refers to the structure —C ⁇ (NR X )N(R X R Y ) wherein R X and R Y have been defined above.
  • the term “vicinal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to adjacent carbon atoms.
  • the term “geminal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to the same carbon atom.
  • terminal and “internally” refer to the location of a group within a substituent.
  • a group is terminal when the group is present at the end of the substituent not further bonded to the rest of the chemical structure.
  • Carboxyalkyl i.e., R X O(O)C-alkyl is an example of a carboxy group used terminally.
  • a group is internal when the group is present in the middle of a substituent to at the end of the substituent bound to the rest of the chemical structure.
  • Alkylcarboxy e.g., alkyl-C(O)O— or alkyl-OC(O)—
  • alkylcarboxyaryl e.g., alkyl-C(O)O-aryl- or alkyl-O(CO)-aryl-
  • cyclic group includes mono-, bi-, and tri-cyclic ring systems including cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been previously defined.
  • bridged bicyclic ring system refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged.
  • bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, 2-oxabicyclo[2.2.2]octyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.0 3,7 ]nonyl.
  • a bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heter
  • an “aliphatic chain” refers to a branched or straight aliphatic group (e.g., alkyl groups, alkenyl groups, or alkynyl groups).
  • a straight aliphatic chain has the structure —[CH 2 ] v —, where v is 1-6.
  • a branched aliphatic chain is a straight aliphatic chain that is substituted with one or more aliphatic groups.
  • a branched aliphatic chain has the structure —[CHQ] v - or —[CQQ] v - where Q is hydrogen or an aliphatic group; however, Q shall be an aliphatic group in at least one instance.
  • the term aliphatic chain includes alkyl chains, alkenyl chains, and alkynyl chains, where alkyl, alkenyl, and alkynyl are defined above.
  • each of the specific groups for the variables R 1 , R 2 , X 1 , X 2 , X 3 , and X 4 , and other variables contained therein can be optionally substituted with one or more substituents described herein.
  • Each substituent of a specific group is further optionally substituted with one to three of halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl.
  • an alkyl group can be substituted with alkylsulfanyl and the alkylsulfanyl can be optionally substituted with one to three of halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl.
  • the cycloalkyl portion of a (cycloalkyl)carbonylamino can be optionally substituted with one to three of halo, cyano, alkoxy, hydroxy, nitro, haloalkyl, and alkyl.
  • substituted refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • Specific substituents are described above in the definitions and below in the description of compounds and examples thereof.
  • an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
  • a ring substituent such as a heterocycloalkyl
  • substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • stable or chemically feasible refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient.
  • the interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966).
  • Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970).
  • patient refers to a mammal, including a human.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, (Z) and (E) conformational isomers, and tautomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • the present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I:
  • X 1 is —NR 3A —;
  • X 2 is —CR′ 3B R′ 3C —;
  • X 3 is —CR 4A R 4B —;
  • X 4 is —CR′ 4C R′ 4B —;
  • R 1 is hydrogen, optionally substituted C 1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
  • Each R 2 is independently -Z A R 5 , wherein each Z A is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR A , —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A , —NR A NR A CO—, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, —P(O)(OR A )—, —P(O)(OR A )NR A — or —NR A SO 2 NR A —,
  • Each of R 3A , R′ 3B , and R′ 3C is independently -Z B R 6 , wherein each Z B is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, —P(O)(OR B ), —P(O)(ORB)NR B — or —NR B SO 2 NR
  • Each of R 4A , R′ 4A , R 4B , and R′ 4B is independently -Z C R 7 , wherein each Z C is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, —P(O)(OR C )—, —P(O)(OR C )NR C — or
  • n 1-3;
  • n 1-3;
  • R 1 is hydrogen, optionally substituted C 1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic.
  • R 1 is -Z D R 8 , wherein each Z D is independently a bond or an optionally substituted branched or straight C 1-12 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —CONR D —, —CONR D NR D , —CO 2 —, —OCO—, —NR D CO 2 —, —O—, —NR D CONR D —, —OCONR D —, —NR D NR D —, —NR D CO—, —S—, —SO—, —SO 2 —, —NR D —, —SO 2 NR D —, —NR D SO 2 —, or —NR D SO 2 NR D —.
  • Each R 8 is independently R D , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 .
  • Each R D is independently hydrogen or an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted heterocycloaliphatic.
  • R 1 is an optionally substituted C 1-12 aliphatic. In another embodiments, R 1 is an optionally substituted group selected from C 1-12 alkyl, C 1-12 alkenyl, or C 1-12 alkynyl. In yet another embodiment, R 1 is an optionally substituted C 1-6 alkyl.
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted with a cycloaliphatic, a heterocycloaliphatic, an alkylsulfanyl, an alkoxy, an amino, or combinations thereof, where each of which is optionally substituted.
  • R 1 is an optionally substituted cycloaliphatic.
  • R 1 is an optionally substituted group selected from a monocyclic cycloaliphatic or a bicyclic cycloaliphatic.
  • R 1 is an optionally substituted group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, alkoxycarbonyl, cycloaliphatic, or combinations thereof.
  • R 1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic. In several examples, R 1 is an optionally substituted group selected from 7-10 membered bicyclic cycloalkyl or 7-10 membered bicyclic cycloalkenyl.
  • R 1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, bicyclo[2.2.2]oct-2-ene-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • R 1 is an optionally substituted group selected from monocyclic heterocycloaliphatic or a bicyclic heterocycloaliphatic. In some examples, R 1 is an optionally substituted 3-8 membered monocyclic cycloaliphatic having 1-3 heteroatoms selected from N, O, and S.
  • R 1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
  • R 1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms selected from N, O, and S.
  • R 1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic.
  • R 1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • R 1 is one selected from: hydrogen; cyclohexylmethyl; 3,3-dimethylbutyl; bicyclo[2.2.1]hept-5-en-2-yl; cyclohept-1-yl; bicyclo[2.2.1]heptane-2-yl; 1-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; 3-methylbutyl; (tetrahydro-2H-pyran-4-yl)ethyl; 4-(methyl(sulfanyl))butyl; 3,7-dimethyl-7-methoxyoctyl; (tetrahydro-2H-thiopyran-4-yl)ethyl; cyclohexyl; cycloheptyl; cyclopentyl; (N,N-dimethylaminocarbonyl)piperidine-4-yl; N-acetylpipe
  • X 1 is —NR 3A —, and X 2 is —CR′ 3B R′ 3C —; wherein each of R 3A , R′ 3B , and R′ 3C is independently -Z B R 6 , wherein each Z B is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, —
  • R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group
  • one of R 3A or R′ 3B and R 4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic ring or an optionally substituted 3-10 membered heterocycloaliphatic ring.
  • X 3 is —CR 4A R 4B —, and X 4 is —CR′ 4C R′ 4B —; wherein each of R 4A , R′ 4A , R 4B , and R′ 4B is independently -Z C R 7 , wherein each Z C is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C
  • X 1 is —NR 3A — and X 2 is —CR′ 3A R′ 3B —.
  • X 1 is —NR 3A — and X 2 is —CR′ 3B R′ 3C —, wherein R 3B and R 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 1 is —NR 3A — and X 2 is —CR′ 3B R′ 3C —, wherein each of R′ 3B and R′ 3C is hydrogen.
  • X 1 is —NR 3A —, wherein R 3A is -Z B R 6 , each Z B is independently a bond, or an independently and optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z are optionally and independently replaced by —CO—, —CONR B —, —CO 2 —, —NR B CO 2 —, —SO 2 —, —O—, or —NR B CO—, R 6 is R B , and each R B is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 1 is —NR 3A —, wherein R 3A is -Z B R 6 , each Z B is —CO—, —CONH—, —CO 2 —, —NHCO 2 —, —SO 2 —, —O—, or —NHCO—, and R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 1 is —NR 3A —, wherein R 3A is Z B R 6 , Z B is —CO— or —CONH—, and R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 2 is —CR′ 3B R′ 3C —, wherein R′ 3B and R′ 3C are each hydrogen, or R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 1 is —NR 3A —, wherein R 3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X 2 is —CR′ 3B R′ 3C —, wherein each of R′ 3B and R′ 3C are hydrogen or R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 3 is —CR 4A R 4B , wherein R 4A and R 4B together with the carbon atom to which they are attached form a carbonyl group, or each of R 4A and R 4B is hydrogen.
  • X 4 is —CR′ 4A R′ 4B —, wherein each of R′ 4A and R′ 4B are hydrogen.
  • each R 2 is hydrogen or optionally substituted C 1-6 aliphatic.
  • R 2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
  • each R 2 is hydrogen.
  • n 1-3.
  • n 1-3.
  • m is 1, 2, or 3.
  • n is 1, 2, or 3.
  • m+n is 4.
  • m and n are 2.
  • q is 0, 1, 2, 3, or 4.
  • q is 0 or 4.
  • Another aspect of the present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I-A:
  • R 1 , R 2 , R 3A , m, n, and q are define above in formula I.
  • Another aspect of the present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I-B:
  • R 1 , R 2 , R 3A , m, n, and q are define above in formula I.
  • the present invention provides a compound of formula I:
  • X 1 is —NR 3A —;
  • X 2 is —CR′ 3B R′ 3C —;
  • X 3 is —CR 4A R 4B —;
  • X 4 is —CR′ 4C R′ 4B —;
  • R 1 is hydrogen, optionally substituted C 1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
  • Each R 2 is independently Z A R 5 , wherein each Z A is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR A , —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A , —NR A NR A CO, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, —P(O)(OR A )—, —P(O)(OR A )NR A — or —NR A SO 2 NR A ,
  • Each of R 3A , R′ 3B , and R′ 3C is independently -Z B R 6 , wherein each Z B is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, —P(O)(OR B )—, —P(O)(OR B )NR B — or —NR B SO
  • Each of R 4A , R′ 4A , R 4B , and R′ 4B is independently -Z C R 7 , wherein each Z C is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, —P(O)(OR C )—, —P(O)(OR C )NR C — or
  • n 1-3;
  • n 1-3;
  • R 1 is hydrogen, optionally substituted C 1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic.
  • R 1 is -Z D R 8 , wherein each Z D is independently a bond or an optionally substituted branched or straight C 1-12 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —CONR D —, —CONR D NR D N D —, —CO 2 —, —OCO—, —NR D CO 2 —, —O—, —NR D CONR D —, —OCONR D —, —NR D NR D —, —NR D CO—, —S—, —SO—, —SO 2 —, —NR D —, —SO 2 NR D —, —NR D SO 2 —, or —NR D SO 2 NR D —.
  • Each R 8 is independently R D , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 .
  • Each R D is independently hydrogen or an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted heterocycloaliphatic.
  • R 1 is an optionally substituted C 1-12 aliphatic. In another embodiment, R 1 is an optionally substituted group selected from C 1-12 alkyl, C 1-12 alkenyl, or C 1-12 alkynyl. In yet another embodiment, R 1 is an optionally substituted C 1-6 alkyl.
  • R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted with a cycloaliphatic, a heterocycloaliphatic, an alkylsulfanyl, an alkoxy, an amino, or combinations thereof, where each of which is optionally substituted.
  • R 1 is an optionally substituted cycloaliphatic.
  • R 1 is an optionally substituted group selected from a monocyclic cycloaliphatic or a bicyclic cycloaliphatic.
  • R 1 is an optionally substituted group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, alkoxycarbonyl, cycloaliphatic, or combinations thereof.
  • R 1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic. In several examples, R 1 is an optionally substituted group selected from 7-10 membered bicyclic cycloalkyl or 7-10 membered bicyclic cycloalkenyl.
  • R 1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, bicyclo[2.2.2]oct-2-ene-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • R 1 is an optionally substituted group selected from monocyclic heterocycloaliphatic or a bicyclic heterocycloaliphatic. In some examples, R 1 is an optionally substituted 3-8 membered monocyclic cycloaliphatic having 1-3 heteroatoms selected from N, O, and S.
  • R 1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
  • R 1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms selected from N, O, and S.
  • R 1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic.
  • R 1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • R 1 is one selected from: hydrogen; cyclohexylmethyl; 3,3-dimethylbutyl; bicyclo[2.2.1]hept-5-en-2-yl; cyclohept-1-yl; bicyclo[2.2.1]heptane-2-yl; 1-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; 3-methylbutyl; (tetrahydro-2H-pyran-4-yl)ethyl; 4-(methyl(sulfanyl))butyl; 3,7-dimethyl-7-methoxyoctyl; (tetrahydro-2H-thiopyran-4-yl)ethyl; cyclohexyl; cycloheptyl; cyclopentyl; (N,N-dimethylaminocarbonyl)piperidine-4-yl; N-acetylpipe
  • X 1 is —NR 3A —, and X 2 is —CR′ 3B R′ 3C —; wherein each of R 3A , R′ 3B , and R′ 3C is independently -Z B R 6 , wherein each Z B is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, —
  • R 2 and R 3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic
  • R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group
  • one of R 3A or R′ 3B and R 4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic ring or an optionally substituted 3-10 membered heterocycloaliphatic ring.
  • X 3 is —CR 4A R 4B —, and X 4 is —CR′ 4C R′ 4B —; wherein each of R 4A , R′ 4A , R 4B , and R′ 4B is independently -Z C R 7 , wherein each Z C is independently a bond or is an optionally substituted C 1-8 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C
  • X 1 is —NR 3A — and X 2 is —CR′ 3A R′ 3B —.
  • X 1 is —NR 3A — and
  • X 2 is —CR′ 3B R′ 3C —, wherein R 3B and R 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 1 is —NR 3A — and X 2 is —CR′ 3B R′ 3C —, wherein each of R′ 3B and R′ 3C is hydrogen.
  • X 1 is —NR 3A —, wherein R 3A is -Z B R 6 , each Z B is independently a bond, or an independently and optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CONR B —, —CO 2 —, —NR B CO 2 —, —SO 2 —, —O—, or —NR B CO—, R 6 is R B , and each R B is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 1 is —NR 3A —, wherein R 3A is -Z B R 6 , each Z B is —CO—, —CONH—, —CO 2 —, —NHCO 2 —, —SO 2 —, —O—, or —NHCO—, and R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 1 is —NR 3A —, wherein R 3A is Z B R 6 , Z B is —CO— or —CONH—, and R 6 is hydrogen or optionally substituted C 1-3 aliphatic.
  • X 2 is —CR′ 3B R′ 3C —, wherein R′ 3B and R′ 3C are each hydrogen, or R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 1 is —NR 3A —, wherein R 3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X 2 is —CR′ 3B R′ 3C —, wherein each of R′ 3B and R′ 3C are hydrogen or R′ 3B and R′ 3C together with the carbon atom to which they are attached form a carbonyl group.
  • X 3 is —CR 4A R 4B , wherein R 4A and R 4B together with the carbon atom to which they are attached form a carbonyl group, or each of R 4A and R 4B is hydrogen.
  • X 4 is —CR′ 4A R′ 4B —, wherein each of R′ 4A and R′ 4B are hydrogen.
  • R 2 is hydrogen or optionally substituted C 1-6 aliphatic.
  • R 2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
  • n 1-3.
  • n 1-3.
  • m is 1, 2, or 3.
  • n is 1, 2, or 3.
  • m+n is 4.
  • m and n are 2.
  • q is 0, 1, 2, 3, or 4.
  • q is 0 or 4.
  • Another aspect of the present invention provides compounds useful for modulating the activity of a muscarinic receptor according to formula I-A:
  • R 1 , R 2 , R 3A , m, n, and q are define above in formula I.
  • Another aspect of the present invention provides compounds useful for modulating the activity of a muscarinic receptor according to formula I-B:
  • R 1 , R 2 , R 3A , m, n, and q are define above in formula I.
  • the present invention includes within its scope pharmaceutically acceptable prodrugs of the compounds of the present invention.
  • a “pharmaceutically acceptable prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof.
  • Preferred prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal or which enhance delivery of the parent compound to a biological compartment relative to the parent species.
  • compositions of this invention refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pec
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (C 1-4 alkyl) 4 salts.
  • alkali metal e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium and N + (C 1-4 alkyl) 4 salts This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions of this invention are formulated for oral administration.
  • compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the modulator can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as “appropriate for the disease, or condition, being treated.”
  • the compounds of formulae (I, I-A, and I-B) are selective modulators of M 1 , M 2 and M 4 . More preferably, the compounds of formulae (I, I-A, and I-B) are effective modulators of M 1 and/or M 4 . Yet more preferably, certain compounds of formulae (I, I-A, I-B) are selective modulators of M 1 . Or, preferably, certain compounds of formulae (I, I-A, and I-B) are selective modulators of M 4 .
  • muscarinic receptors i.e., an agonist
  • a muscarinic receptor i.e., an agonist
  • selective means a measurably greater ability to modulate one muscarinic receptor subtype when compared to the other muscarinic receptor subtypes.
  • selective M 4 agonist means a compound that has a measurably greater ability to act as an M 4 agonist when compared to that compound's agonist activity with the other muscarinic receptor subtype(s).
  • the present invention provides a method of treating a muscarinic receptor mediated disease in a mammal, such as a human, including the step of administering to said mammal a composition comprising a compound of formulae (I, I-A, and I-B) or an embodiment thereof as set forth herein.
  • the present invention provides a method of treating a disease mediated by a muscarinic receptor including the step of administering to said mammal a composition comprising a compound of formulae (I, I-A, and I-B), or other embodiments thereof as set forth above.
  • said disease is mediated by M 1
  • said disease is mediated by M 4 .
  • the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, sudden infant death syndrome, Parkinson's disease, peripheral disorders such as reduction of intra ocular-pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, wherein said method comprises the step of contacting said patient with a compound according to the present invention.
  • ADHD Attention Deficit Hyperactivity Disorder
  • various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles
  • the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradycardia, gastric acid secretion, asthma, or GI disturbances.
  • said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradycardia, gastric acid secretion, asthma, or GI disturbances.
  • the present invention is useful for treating or reducing the severity of psychosis, Alzheimer's disease, pain, or Parkinson's disease.
  • the dimethylcarbamate J failed to be synthesized by the treatment with dimethylcarbamyl chloride (1.5-4 equivalent) with the azepine F (180 mg) in the presence of Hunig's base (3 equivalent) or sodium hydride (3 equivalent) under reflux in THF and HMPA.
  • the mixture was treated with acetyl chloride (0.14 ml, 1 mmol) to give tert-butyl 1-acetyl-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate G (257 mg, crude).
  • Table 2 illustrates synthetic methods used to produce exemplary compounds of formula I.
  • CHO cells expressing muscarinic receptors are grown as monolayers in tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO 2 and passaged every 3-5 days.
  • the growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with Fetal Bovine Serum (Hyclone, Cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 ⁇ g/ml of Streptomycin (GIBCO Cat# 15140-122).
  • the recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 ⁇ g/ml zeocin and 500 ⁇ g/ml G418 (MI-CHO), 4 ⁇ g/ml puromycin, 50 ⁇ g/ml zeocin and 2.5 ⁇ g/ml blasticidin (M2 and M4-CHO) or 50 ⁇ g/ml zeocin and 4 ⁇ g/ml puromycin (M3 and M5-CHO).
  • the cells are washed with a plate washer (Bioteck Instruments, ELX 405) using bath 1 buffer (140-mM NaCl, 4.5-mM KCl, 2-mM CaCl 2 , 1-mM MgCl 2 , 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH) containing 1 mM Probenecid.
  • bath 1 buffer 140-mM NaCl, 4.5-mM KCl, 2-mM CaCl 2 , 1-mM MgCl 2 , 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH
  • the calcium dye Fluo-3 25 ⁇ l well of Fluo-3 AM at 4 ⁇ M, Molecular Probes F-1241, in Bath 1 buffer containing 1 mM Probenecid
  • Bath 1 buffer containing 1 mM Probenecid
  • cells can be loaded with the calcium indicator from Molecular Devices (Calcium 3 Assay Reagents, Cat # R7181) adding 5 ⁇ l of a 5 ⁇ solution dye in Bath 1 containing 1 mM Probenecid (10 ml per dye flask cat# R7182 to generate a solution 20 ⁇ ) to 20 ⁇ l of the same buffer. After loading for 60 min, the experiment can be run without having to remove the dye.
  • Compounds are prepared at a 2 ⁇ fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in bath 1 containing 1 mM probenecid.
  • the final concentration DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate.
  • the reconstituted compounds are added (25 ⁇ l compound/well) to the cell assay plate (containing 25 ⁇ l/well) using the multi-channel robotic system of the FLIPR 3 Instrument (Molecular Devices, Sunnyvale, Calif.).
  • the reconstituted compounds are added (25 ⁇ l compound/well) to the assay plate and pre-incubated for 15 min prior to adding 25 ⁇ l of Carbachol at 3 ⁇ the EC80 for each muscarinic subtype.
  • the compounds can be co-applied simultaneously with the agonist.
  • the fluorescence is recorded for 60 sec (excitation wavelength is 488 nM and emission wavelength 540 nm) using the FLIPR 3 instrument.
  • the potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M 1 to M 5 cells). Compounds were also screened for activity on other proteins such as other GPCRs and ion channels to determine selectivity on M 4 receptors.
  • the compounds of the present invention were found to modulate the M 1 and/or M 4 muscarinic receptors selectively over the other receptor types.
  • Examples of activities and efficacies of the muscarinic compounds of formulae (I, I-A, and I-B) on modulating M 1 and M 4 receptors are shown below in Table 4.
  • the compound activity for the M 1 and M 4 is illustrated with “+++” if activity was measured to be less than 2.0 ⁇ M, “++” if activity was measured to be from 2.0 ⁇ M to 10.0 ⁇ M, “+” if activity was measured to be greater than 10.0 ⁇ M, and “ ⁇ ” if no data was available.
  • the efficacy for M 1 and M 4 modulation is illustrated with “+++” if efficacy was calculated to be greater than 100%, “++” if efficacy was calculated to be from 100% to 25%, “+” if efficacy was calculated to be less than 25%, and “ ⁇ ” if no data was available. It should be noted that 100% efficacy is the maximum response obtained with the Carbachol control.

Abstract

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Description

    CLAIM OF PRIORITY
  • This application claims priority to U.S. Provisional Application Ser. No. 60/838,701 filed on Aug. 18, 2006, which is hereby incorporated by reference.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
    • BACKGROUND OF THE INVENTION
  • The neurotransmitter acetylcholine binds to two types of cholinergic receptors: the ionotropic family of nicotinic receptors and the metabotropic family of muscarinic receptors. Muscarinic receptors belong to the large superfamily of plasma membrane-bound G protein coupled receptors (GPCRs). To date, five subtypes of muscarinic receptors (M1-M5) have been cloned and sequenced from a variety of species, and show a remarkably high degree of homology across species and receptor subtype. These M1-M5 muscarinic receptors are predominantly expressed within the parasympathetic nervous system which exerts excitatory and inhibitory control over the central and peripheral tissues and participate in a number of physiologic functions, including heart rate, arousal, cognition, sensory processing, and motor control.
  • Muscarinic agonists such as muscarine and pilocarpine, and antagonists, such as atropine have been known for over a century, but little progress has been made in the discovery of receptor subtype-selective compounds, thereby making it difficult to assign specific functions to the individual receptors. See, e.g., DeLapp, N. et al., “Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System,” J. Med. Chem., 43(23), pp. 4333-4353 (2000); Hulme, E. C. et al., “Muscarinic Receptor Subtypes,” Ann. Rev. Pharmacol. Toxicol., 30, pp. 633-673 (1990); Caulfield, M. P. et al., “Muscarinic Receptors-Characterization, Coupling, and Function,” Pharmacol. Ther., 58, pp. 319-379 (1993); Caulfield, M. P. et al., International Union of Pharmacology. XVII. “Classification of Muscarinic Acetylcholine Receptors,” Pharmacol. Rev., 50, pp. 279-290 (1998), the disclosures of which are incorporated herein by reference.
  • The Muscarinic family of receptors is the target of a large number of pharmacological agents used for various diseases, including leading drugs for COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors). Despite the large therapeutic value of this family, cholinergic drugs are limited by the lack of selectivity of these agents, with significant activation of the parasympathetic autonomous system and elevated incidence of adverse effects. The molecular cloning of the muscarinic receptors and the identification of the physiological role of specific isoforms using knock-out mice, has recently delineated novel opportunities for selective muscarinic ligands, and has helped to define the selectivity profile that is required for enhanced efficacy and reduced side effects.
  • There is a need for modulators of muscarinic receptors M1-M5. There is also a need for methods for treating muscarinic receptor-mediated diseases.
  • There is also a need for modulators of muscarinic receptors that are selective as to subtypes M1-M5.
    • SUMMARY OF THE INVENTION
  • The present invention provides methods of modulating the activity of a muscarinic receptor (e.g., M1, M2, M3, M4, M5, or combinations thereof) using compounds of formula I:
  • Figure US20080113958A1-20080515-C00001
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, X3, X4, m, n, and q are described below.
    • DETAILED DESCRIPTION I. Definitions
  • For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
  • The term “muscarinic receptor,” without a prefix specifying the receptor subtype, refers to one or more of the five receptor subtypes M1-M5.
  • The term “modulating” as used herein means increasing or decreasing, e.g. activity, by a measurable amount. Compounds that modulate muscarinic activity by increasing the activity of the muscarinic receptors are called agonists. Compounds that modulate muscarinic activity by decreasing the activity of the muscarinic receptors are called antagonists. An agonist interacts with a muscarinic receptor to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding. An antagonist interacts with a muscarinic receptor and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • The phrase “treating or reducing the severity of a muscarinic receptor mediated disease” refers both to treatments for diseases that are directly caused by muscarinic activities and alleviation of symptoms of diseases not directly caused by muscarinic activities. Examples of diseases whose symptoms may be affected by muscarinic activity include, but are not limited to, CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, bradhycardia, gastric acid secretion, asthma, GI disturbances and wound healing.
  • As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • As used herein the term “aliphatic” encompasses the terms alkyl, alkenyl, alkynyl, each of which being optionally substituted as set forth below.
  • As used herein, an “alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms. An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl. An alkyl group can be substituted (i.e., optionally substituted) with one or more substituents such as halo, cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], heterocycloaliphatic [e.g., heterocycloalkyl or heterocycloalkenyl], aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl [e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl], nitro, cyano, amido [e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino alkylaminocarbonyl, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl], amino [e.g., aliphaticamino, cycloaliphaticamino, or heterocycloaliphaticamino], sulfonyl [e.g., aliphatic-SO2—], sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carboxy, carbamoyl, cycloaliphaticoxy, heterocycloaliphaticoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, alkoxycarbonyl, alkylcarbonyloxy, or hydroxy. Without limitation, some examples of substituted alkyls include carboxyalkyl (such as HOOC-alkyl, alkoxycarbonylalkyl, and alkylcarbonyloxyalkyl), cyanoalkyl, hydroxyalkyl, alkoxyalkyl, acylalkyl, aralkyl, (alkoxyaryl)alkyl, (sulfonylamino)alkyl (such as (alkyl-SO2-amino)alkyl), aminoalkyl, amidoalkyl, (cycloaliphatic)alkyl, or haloalkyl.
  • As used herein, an “alkenyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group can be optionally substituted with one or more substituents such as halo, cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], heterocycloaliphatic [e.g., heterocycloalkyl or heterocycloalkenyl], aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, acyl [e.g., (aliphatic)carbonyl, (cycloaliphatic)carbonyl, or (heterocycloaliphatic)carbonyl], nitro, cyano, amido [e.g., (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino alkylaminocarbonyl, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl], amino [e.g., aliphaticamino, cycloaliphaticamino, heterocycloaliphaticamino, or aliphaticsulfonylamino], sulfonyl [e.g., alkyl-SO2—, cycloaliphatic-SO2—, or aryl-SO2—], sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carboxy, carbamoyl, cycloaliphaticoxy, heterocycloaliphaticoxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkoxy, alkoxycarbonyl, alkylcarbonyloxy, or hydroxy. Without limitation, some examples of substituted alkenyls include cyanoalkenyl, alkoxyalkenyl, acylalkenyl, hydroxyalkenyl, aralkenyl, (alkoxyaryl)alkenyl, (sulfonylamino)alkenyl (such as (alkyl-SO2-amino)alkenyl), aminoalkenyl, amidoalkenyl, (cycloaliphatic)alkenyl, or haloalkenyl.
  • As used herein, an “alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl. An alkynyl group can be optionally substituted with one or more substituents such as aroyl, heteroaroyl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, nitro, carboxy, cyano, halo, hydroxy, sulfo, mercapto, sulfanyl [e.g., aliphaticsulfanyl or cycloaliphaticsulfanyl], sulfinyl [e.g., aliphaticsulfinyl or cycloaliphaticsulfinyl], sulfonyl [e.g., aliphatic-SO2—, aliphaticamino-SO2—, or cycloaliphatic-SO2—], amido [e.g., aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, cycloalkylcarbonylamino, arylaminocarbonyl, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (cycloalkylalkyl)carbonylamino, heteroaralkylcarbonylamino, heteroarylcarbonylamino or heteroarylaminocarbonyl], urea, thiourea, sulfamoyl, sulfamide, alkoxycarbonyl, alkylcarbonyloxy, cycloaliphatic, heterocycloaliphatic, aryl, heteroaryl, acyl [e.g., (cycloaliphatic)carbonyl or (heterocycloaliphatic)carbonyl], amino [e.g., aliphaticamino], sulfoxy, oxo, carboxy, carbamoyl, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, or (heteroaryl)alkoxy.
  • As used herein, an “amido” encompasses both “aminocarbonyl” and “carbonylamino”. These terms when used alone or in connection with another group refers to an amido group such as —N(RX)—C(O)—RY or —C(O)—N(RX)2, when used terminally, and —C(O)—N(RX)— or —N(RX)—C(O)— when used internally, wherein RX and RY are defined below. Examples of amido groups include alkylamido (such as alkylcarbonylamino or alkylaminocarbonyl), (heterocycloaliphatic)amido, (heteroaralkyl)amido, (heteroaryl)amido, (heterocycloalkyl)alkylamido, arylamido, aralkylamido, (cycloalkyl)alkylamido, or cycloalkylamido.
  • As used herein, an “amino” group refers to —NRXRY wherein each of RX and RY is independently hydrogen, aliphatic, cycloaliphatic, (cycloaliphatic)aliphatic, aryl, araliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, heteroaryl, carboxy, sulfanyl, sulfinyl, sulfonyl, (aliphatic)carbonyl, (cycloaliphatic)carbonyl, ((cycloaliphatic)aliphatic)carbonyl, arylcarbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, (heteroaryl)carbonyl, or (heteroaraliphatic)carbonyl, each of which being defined herein and being optionally substituted. Examples of amino groups include alkylamino, dialkylamino, or arylamino. When the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by —NRX—. RX has the same meaning as defined above.
  • As used herein, an “aryl” group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl, naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); and tricyclic (e.g., fluorenyl tetrahydrofluorenyl, or tetrahydroanthracenyl, anthracenyl) ring systems in which the monocyclic ring system is aromatic or at least one of the rings in a bicyclic or tricyclic ring system is aromatic. The bicyclic and tricyclic groups include benzofused 2-3 membered carbocyclic rings. For example, a benzofused group includes phenyl fused with two or more C4-8 carbocyclic moieties. An aryl is optionally substituted with one or more substituents including aliphatic [e.g., alkyl, alkenyl, or alkynyl]; cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocyclic ring of a benzofused bicyclic or tricyclic aryl); nitro; carboxy; amido; acyl [e.g., aliphaticcarbonyl; (cycloaliphatic)carbonyl; ((cycloaliphatic)aliphatic)carbonyl; (araliphatic)carbonyl; (heterocycloaliphatic)carbonyl; ((heterocycloaliphatic)aliphatic)carbonyl; or (heteroaraliphatic)carbonyl]; sulfonyl [e.g., aliphatic-SO2— or amino-SO2—]; sulfinyl [e.g., aliphatic-S(O)— or cycloaliphatic-S(O)—]; sulfanyl [e.g., aliphatic-S—]; cyano; halo; hydroxy; mercapto; sulfoxy; urea; thiourea; sulfamoyl; sulfamide; or carbamoyl. Alternatively, an aryl can be unsubstituted.
  • Non-limiting examples of substituted aryls include haloaryl [e.g., mono-, di (such as p,m-dihaloaryl), and (trihalo)aryl]; (carboxy)aryl [e.g., (alkoxycarbonyl)aryl, ((aralkyl)carbonyloxy)aryl, and (alkoxycarbonyl)aryl]; (amido)aryl [e.g., (aminocarbonyl)aryl, (((alkylamino)alkyl)aminocarbonyl)aryl, (alkylcarbonyl)aminoaryl, (arylaminocarbonyl)aryl, and (((heteroaryl)amino)carbonyl)aryl]; aminoaryl [e.g., ((alkylsulfonyl)amino)aryl or ((dialkyl)amino)aryl]; (cyanoalkyl)aryl; (alkoxy)aryl; (sulfamoyl)aryl [e.g., (aminosulfonyl)aryl]; (alkylsulfonyl)aryl; (cyano)aryl; (hydroxyalkyl)aryl; ((alkoxy)alkyl)aryl; (hydroxy)aryl, ((carboxy)alkyl)aryl; (((dialkyl)amino)alkyl)aryl; (nitroalkyl)aryl; (((alkylsulfonyl)amino)alkyl)aryl; ((heterocycloaliphatic)carbonyl)aryl; ((alkylsulfonyl)alkyl)aryl; (cyanoalkyl)aryl; (hydroxyalkyl)aryl; (alkylcarbonyl)aryl; alkylaryl; (trihaloalkyl)aryl; p-amino-m-alkoxycarbonylaryl; p-amino-m-cyanoaryl; p-halo-m-aminoaryl; or (m-(heterocycloaliphatic)-o-(alkyl))aryl.
  • As used herein, an “araliphatic” such as an “aralkyl” group refers to an aliphatic group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. “Aliphatic,” “alkyl,” and “aryl” are defined herein. An example of an araliphatic such as an aralkyl group is benzyl.
  • As used herein, an “aralkyl” group refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” have been defined above. An example of an aralkyl group is benzyl. An aralkyl is optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl, including carboxyalkyl, hydroxyalkyl, or haloalkyl such as trifluoromethyl], cycloaliphatic [e.g., cycloalkyl or cycloalkenyl], (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, amido [e.g., aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, or heteroaralkylcarbonylamino], cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • As used herein, a “bicyclic ring system” includes 8-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common). Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic aryls, and bicyclic heteroaryls.
  • As used herein, a “cycloaliphatic” group encompasses a “cycloalkyl” group and a “cycloalkenyl” group, each of which being optionally substituted as set forth below.
  • As used herein, a “cycloalkyl” group refers to a saturated carbocyclic mono- or bicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, norbornyl, cubyl, octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2.]decyl, bicyclo[2.2.2]octyl, adamantyl, azacycloalkyl, or ((aminocarbonyl)cycloalkyl)cycloalkyl. A “cycloalkenyl” group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bonds. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl, bicyclo[2.2.2]octenyl, or bicyclo[3.3.1]nonenyl. A cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl], cycloaliphatic, (cycloaliphatic) aliphatic, heterocycloaliphatic, (heterocycloaliphatic) aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido [e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic)aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbonylamino, ((heterocycloaliphatic)aliphatic)carbonylamino, (heteroaryl)carbonylamino, or (heteroaraliphatic)carbonylamino], nitro, carboxy [e.g., HOOC—, alkoxycarbonyl, or alkylcarbonyloxy], acyl [e.g., (cycloaliphatic)carbonyl, ((cycloaliphatic) aliphatic)carbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)carbonyl], cyano, halo, hydroxy, mercapto, sulfonyl [e.g., alkyl-SO2— and aryl-SO2—], sulfinyl [e.g., alkyl-S(O)—], sulfanyl [e.g., alkyl-S—], sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • As used herein, “cyclic moiety” includes cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been defined previously.
  • As used herein, the term “heterocycloaliphatic” encompasses a heterocycloalkyl group and a heterocycloalkenyl group, each of which being optionally substituted as set forth below.
  • As used herein, a “heterocycloalkyl” group refers to a 3-10 membered mono- or bicylic (fused or bridged) (e.g., 5- to 10-membered mono- or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof). Examples of a heterocycloalkyl group include piperidyl, piperazyl, tetrahydropyranyl, tetrahydrofuryl, 1,4-dioxolanyl, 1,4-dithianyl, 1,3-dioxolanyl, oxazolidyl, isoxazolidyl, morpholinyl, thiomorpholyl, octahydrobenzofuryl, octahydrochromenyl, octahydrothiochromenyl, octahydroindolyl, octahydropyrindinyl, decahydroquinolinyl, octahydrobenzo[b]thiopheneyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A monocyclic heterocycloalkyl group can be fused with a phenyl moiety such as tetrahydroisoquinoline. A “heterocycloalkenyl” group, as used herein, refers to a mono- or bicylic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom (e.g., N, O, or S). Monocyclic and bicycloheteroaliphatics are numbered according to standard chemical nomenclature.
  • A heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl], cycloaliphatic, (cycloaliphatic)aliphatic, heterocycloaliphatic, (heterocycloaliphatic)aliphatic, aryl, heteroaryl, alkoxy, (cycloaliphatic)oxy, (heterocycloaliphatic)oxy, aryloxy, heteroaryloxy, (araliphatic)oxy, (heteroaraliphatic)oxy, aroyl, heteroaroyl, amino, amido [e.g., (aliphatic)carbonylamino, (cycloaliphatic)carbonylamino, ((cycloaliphatic) aliphatic)carbonylamino, (aryl)carbonylamino, (araliphatic)carbonylamino, (heterocycloaliphatic)carbonylamino, ((heterocycloaliphatic) aliphatic)carbonylamino, (heteroaryl)carbonylamino, or (heteroaraliphatic)carbonylamino], nitro, carboxy [e.g., HOOC—, alkoxycarbonyl, or alkylcarbonyloxy], acyl [e.g., (cycloaliphatic)carbonyl, ((cycloaliphatic) aliphatic)carbonyl, (araliphatic)carbonyl, (heterocycloaliphatic)carbonyl, ((heterocycloaliphatic)aliphatic)carbonyl, or (heteroaraliphatic)carbonyl], nitro, cyano, halo, hydroxy, mercapto, sulfonyl [e.g., alkylsulfonyl or arylsulfonyl], sulfinyl [e.g., alkylsulfinyl], sulfanyl [e.g., alkylsulfanyl], sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • A “heteroaryl” group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring system having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof) and in which the monocyclic ring system is aromatic or at least one of the rings in the bicyclic or tricyclic ring systems is aromatic. A heteroaryl group includes a benzofused ring system having 2 to 3 rings. For example, a benzofused group includes benzo fused with one or two 4 to 8 membered heterocycloaliphatic moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl). Some examples of heteroaryl are azetidinyl, pyridyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl, cinnolyl, quinolyl, quinazolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo-1,2,5-thiadiazolyl, or 1,8-naphthyridyl.
  • Without limitation, monocyclic heteroaryls include furyl, thiophenyl, 2H-pyrrolyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4-H-pranyl, pyridyl, pyridazyl, pyrimidyl, pyrazolyl, pyrazyl, or 1,3,5-triazyl. Monocyclic heteroaryls are numbered according to standard chemical nomenclature.
  • Without limitation, bicyclic heteroaryls include indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, indolizyl, isoindolyl, indolyl, benzo[b]furyl, bexo[b]thiophenyl, indazolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl, quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, 1,8-naphthyridyl, or pteridyl. Bicyclic heteroaryls are numbered according to standard chemical nomenclature.
  • A heteroaryl is optionally substituted with one or more substituents such as aliphatic [e.g., alkyl, alkenyl, or alkynyl]; cycloaliphatic; (cycloaliphatic)aliphatic; heterocycloaliphatic; (heterocycloaliphatic)aliphatic; aryl; heteroaryl; alkoxy; (cycloaliphatic)oxy; (heterocycloaliphatic)oxy; aryloxy; heteroaryloxy; (araliphatic)oxy; (heteroaraliphatic)oxy; aroyl; heteroaroyl; amino; oxo (on a non-aromatic carbocyclic or heterocyclic ring of a bicyclic or tricyclic heteroaryl); carboxy; amido; acyl [e.g., aliphaticcarbonyl; (cycloaliphatic)carbonyl; ((cycloaliphatic)aliphatic)carbonyl; (araliphatic)carbonyl; (heterocycloaliphatic)carbonyl; ((heterocycloaliphatic)aliphatic)carbonyl; or (heteroaraliphatic)carbonyl]; sulfonyl [e.g., aliphaticsulfonyl or aminosulfonyl]; sulfinyl [e.g., aliphaticsulfinyl]; sulfanyl [e.g., aliphaticsulfanyl]; nitro; cyano; halo; hydroxy; mercapto; sulfoxy; urea; thiourea; sulfamoyl; sulfamide; or carbamoyl. Alternatively, a heteroaryl can be unsubstituted.
  • Non-limiting examples of substituted heteroaryls include (halo)heteroaryl [e.g., mono- and di-(halo)heteroaryl]; (carboxy)heteroaryl [e.g., (alkoxycarbonyl)heteroaryl]; cyanoheteroaryl; aminoheteroaryl [e.g., ((alkylsulfonyl)amino)heteroaryl and ((dialkyl)amino)heteroaryl]; (amido)heteroaryl [e.g., aminocarbonylheteroaryl, ((alkylcarbonyl)amino)heteroaryl, ((((alkyl)amino)alkyl)aminocarbonyl)heteroaryl, (((heteroaryl)amino)carbonyl)heteroaryl, ((heterocycloaliphatic)carbonyl)heteroaryl, and ((alkylcarbonyl)amino)heteroaryl]; (cyanoalkyl)heteroaryl; (alkoxy)heteroaryl; (sulfamoyl)heteroaryl [e.g., (aminosulfonyl)heteroaryl]; (sulfonyl)heteroaryl [e.g., (alkylsulfonyl)heteroaryl]; (hydroxyalkyl)heteroaryl; (alkoxyalkyl)heteroaryl; (hydroxy)heteroaryl; ((carboxy)alkyl)heteroaryl; (((dialkyl)amino)alkyl]heteroaryl; (heterocycloaliphatic)heteroaryl; (cycloaliphatic)heteroaryl; (nitroalkyl)heteroaryl; (((alkylsulfonyl)amino)alkyl)heteroaryl; ((alkylsulfonyl)alkyl)heteroaryl; (cyanoalkyl)heteroaryl; (acyl)heteroaryl [e.g., (alkylcarbonyl)heteroaryl]; (alkyl)heteroaryl, and (haloalkyl)heteroaryl [e.g., trihaloalkylheteroaryl].
  • A “heteroaraliphatic (such as a heteroaralkyl group) as used herein, refers to an aliphatic group (e.g., a C1-4 alkyl group) that is substituted with a heteroaryl group. “Aliphatic,” “alkyl,” and “heteroaryl” have been defined above.
  • A “heteroaralkyl” group, as used herein, refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above. A heteroaralkyl is optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • As used herein, an “acyl” group refers to a formyl group or RX—C(O)— (such as alkyl-C(O)—, also referred to as “alkylcarbonyl”) where RX and “alkyl” have been defined previously. Acetyl and pivaloyl are examples of acyl groups.
  • As used herein, an “aroyl” or “heteroaroyl” refers to an aryl-C(O)— or a heteroaryl-C(O)—. The aryl and heteroaryl portion of the aroyl or heteroaroyl is optionally substituted as previously defined.
  • As used herein, an “alkoxy” group refers to an alkyl-O— group where “alkyl” has been defined previously.
  • As used herein, a “carbamoyl” group refers to a group having the structure —O—CO—NRXRY or —NRX—CO—O—RZ wherein RX and RY have been defined above and RZ can be aliphatic, aryl, araliphatic, heterocycloaliphatic, heteroaryl, or heteroaraliphatic.
  • As used herein, a “carboxy” group refers to —COOH, —COORX, —OC(O)H, —OC(O)RX when used as a terminal group; or —OC(O)— or —C(O)O— when used as an internal group.
  • As used herein, a “haloaliphatic” group refers to an aliphatic group substituted with 1-3 halogen. For instance, the term haloalkyl includes the group —CF3.
  • As used herein, a “mercapto” group refers to —SH.
  • As used herein, a “sulfo” group refers to —SO3H or —SO3RX when used terminally or —S(O)3— when used internally.
  • As used herein, a “sulfamide” group refers to the structure —NRX—S(O)2—NRYRZ when used terminally and —NRX—S(O)2—NRY— when used internally, wherein RX, RY, and RZ have been defined above.
  • As used herein, a “sulfonamide” group refers to the structure —S(O)2—NRXRY or —NRX—S(O)2—RZ when used terminally; or —S(O)2—NRX— or —NRX—S(O)2— when used internally, wherein RX, RY, and RZ are defined above.
  • As used herein a “sulfanyl” group refers to —S—RX when used terminally and —S— when used internally, wherein RX has been defined above. Examples of sulfanyls include aliphatic-S—, cycloaliphatic-S—, aryl-S—, or the like.
  • As used herein a “sulfinyl” group refers to —S(O)—RX when used terminally and —S(O)— when used internally, wherein RX has been defined above. Exemplary sulfinyl groups include aliphatic-S(O)—, aryl-S(O)—, (cycloaliphatic(aliphatic))-S(O)—, cycloalkyl-S(O)—, heterocycloaliphatic-S(O)—, heteroaryl-S(O)—, or the like.
  • As used herein, a “sulfonyl” group refers to —S(O)2—RX when used terminally and —S(O)2— when used internally, wherein RX has been defined above. Exemplary sulfonyl groups include aliphatic-S(O)2—, aryl-S(O)2—, (cycloaliphatic(aliphatic))-S(O)2—, cycloaliphatic-S(O)2—, heterocycloaliphatic-S(O)2—, heteroaryl-S(O)2—, (cycloaliphatic(amido(aliphatic)))-S(O)2— or the like.
  • As used herein, a “sulfoxy” group refers to —O—SO—RX or —SO—O—RX, when used terminally and —O—S(O)— or —S(O)—O— when used internally, where RX has been defined above.
  • As used herein, a “halogen” or “halo” group refers to fluorine, chlorine, bromine or iodine.
  • As used herein, an “alkoxycarbonyl,” which is encompassed by the term carboxy, used alone or in connection with another group refers to a group such as alkyl-O—C(O)—.
  • As used herein, an “alkoxyalkyl” refers to an alkyl group such as alkyl-O-alkyl-, wherein alkyl has been defined above.
  • As used herein, a “carbonyl” refer to —C(O)—.
  • As used herein, an “oxo” refers to ═O.
  • As used herein, an “aminoalkyl” refers to the structure (RX)2N-alkyl-.
  • As used herein, a “cyanoalkyl” refers to the structure (NC)-alkyl-.
  • As used herein, a “urea” group refers to the structure —NRX—CO—NRYRZ and a “thiourea” group refers to the structure —NRX—CS—NRYRZ when used terminally and —NRX—CO—NRY— or —NRX—CS—NRY— when used internally, wherein RX, RY, and RZ have been defined above.
  • As used herein, a “guanidine” group refers to the structure —N═C(N(RXRY))N(RXRY) or —NRX—C(═NRX)NRXRY wherein RX and RY have been defined above.
  • As used herein, the term “amidino” group refers to the structure —C═(NRX)N(RXRY) wherein RX and RY have been defined above.
  • In general, the term “vicinal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to adjacent carbon atoms.
  • In general, the term “geminal” refers to the placement of substituents on a group that includes two or more carbon atoms, wherein the substituents are attached to the same carbon atom.
  • The terms “terminally” and “internally” refer to the location of a group within a substituent. A group is terminal when the group is present at the end of the substituent not further bonded to the rest of the chemical structure. Carboxyalkyl, i.e., RXO(O)C-alkyl is an example of a carboxy group used terminally. A group is internal when the group is present in the middle of a substituent to at the end of the substituent bound to the rest of the chemical structure. Alkylcarboxy (e.g., alkyl-C(O)O— or alkyl-OC(O)—) and alkylcarboxyaryl (e.g., alkyl-C(O)O-aryl- or alkyl-O(CO)-aryl-) are examples of carboxy groups used internally.
  • As used herein, “cyclic group” includes mono-, bi-, and tri-cyclic ring systems including cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been previously defined.
  • As used herein, a “bridged bicyclic ring system” refers to a bicyclic heterocyclicalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged. Examples of bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, 2-oxabicyclo[2.2.2]octyl, 1-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl. A bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkylalkyl)carbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkylalkyl)carbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • As used herein, an “aliphatic chain” refers to a branched or straight aliphatic group (e.g., alkyl groups, alkenyl groups, or alkynyl groups). A straight aliphatic chain has the structure —[CH2]v—, where v is 1-6. A branched aliphatic chain is a straight aliphatic chain that is substituted with one or more aliphatic groups. A branched aliphatic chain has the structure —[CHQ]v- or —[CQQ]v- where Q is hydrogen or an aliphatic group; however, Q shall be an aliphatic group in at least one instance. The term aliphatic chain includes alkyl chains, alkenyl chains, and alkynyl chains, where alkyl, alkenyl, and alkynyl are defined above.
  • The phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” As described herein, compounds of the invention can optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. As described herein, the variables in formulae (I, I-A, and I-B), e.g., R1, R2, X1, X2, X3, and X4, and other variables contained therein encompass specific groups, such as alkyl and aryl. Unless otherwise noted, each of the specific groups for the variables R1, R2, X1, X2, X3, and X4, and other variables contained therein can be optionally substituted with one or more substituents described herein. Each substituent of a specific group is further optionally substituted with one to three of halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl. For instance, an alkyl group can be substituted with alkylsulfanyl and the alkylsulfanyl can be optionally substituted with one to three of halo, cyano, oxo, alkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl. As an additional example, the cycloalkyl portion of a (cycloalkyl)carbonylamino can be optionally substituted with one to three of halo, cyano, alkoxy, hydroxy, nitro, haloalkyl, and alkyl. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound.
  • In general, the term “substituted,” whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. A ring substituent, such as a heterocycloalkyl, can be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • The phrase “stable or chemically feasible,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • As used herein, an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970). As used herein, “patient” refers to a mammal, including a human.
  • Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, (Z) and (E) conformational isomers, and tautomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
    • II. Methods
  • A. Generic Description
  • The present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I:
  • Figure US20080113958A1-20080515-C00002
  • a pharmaceutically acceptable salt thereof, wherein
  • X1 is —NR3A—;
  • X2 is —CR′3BR′3C—;
  • X3 is —CR4AR4B—;
  • X4 is —CR′4CR′4B—;
  • R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
  • Each R2 is independently -ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA—,
      • Each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic or carbocyclic ring,
  • Each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB), —P(O)(ORB)NRB— or —NRBSO2NRB—,
      • Each R6 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or
        • One of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic or an optionally substituted 3-10 membered heterocycloaliphatic;
  • Each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—,
      • Each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R4A and R4B together with the carbon atom to which they are attached form a carbonyl group;
  • m is 1-3;
  • n is 1-3; and
  • q is 0-4.
  • B. Specific Description
  • 1. Substituent R1
  • R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic.
  • In some embodiments, R1 is -ZDR8, wherein each ZD is independently a bond or an optionally substituted branched or straight C1-12 aliphatic chain wherein up to two carbon units of ZD are optionally and independently replaced by —CO—, —CS—, —CONRD—, —CONRDNRD, —CO2—, —OCO—, —NRDCO2—, —O—, —NRDCONRD—, —OCONRD—, —NRDNRD—, —NRDCO—, —S—, —SO—, —SO2—, —NRD—, —SO2NRD—, —NRDSO2—, or —NRDSO2NRD—. Each R8 is independently RD, halo, —OH, —NH2, —NO2, —CN, or —OCF3. Each RD is independently hydrogen or an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted heterocycloaliphatic.
  • In some embodiments, R1 is an optionally substituted C1-12 aliphatic. In another embodiments, R1 is an optionally substituted group selected from C1-12 alkyl, C1-12 alkenyl, or C1-12 alkynyl. In yet another embodiment, R1 is an optionally substituted C1-6 alkyl. In several examples, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted with a cycloaliphatic, a heterocycloaliphatic, an alkylsulfanyl, an alkoxy, an amino, or combinations thereof, where each of which is optionally substituted.
  • In some embodiments, R1 is an optionally substituted cycloaliphatic. In several examples, R1 is an optionally substituted group selected from a monocyclic cycloaliphatic or a bicyclic cycloaliphatic. In another example, R1 is an optionally substituted group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, alkoxycarbonyl, cycloaliphatic, or combinations thereof.
  • In some embodiments, R1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic. In several examples, R1 is an optionally substituted group selected from 7-10 membered bicyclic cycloalkyl or 7-10 membered bicyclic cycloalkenyl. In another examples, R1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, bicyclo[2.2.2]oct-2-ene-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • In some embodiments, R1 is an optionally substituted group selected from monocyclic heterocycloaliphatic or a bicyclic heterocycloaliphatic. In some examples, R1 is an optionally substituted 3-8 membered monocyclic cycloaliphatic having 1-3 heteroatoms selected from N, O, and S. In another examples, R1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
  • In some embodiments, R1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms selected from N, O, and S. In several examples, R1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic. In another examples, R1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • In several alternative embodiments, R1 is one selected from: hydrogen; cyclohexylmethyl; 3,3-dimethylbutyl; bicyclo[2.2.1]hept-5-en-2-yl; cyclohept-1-yl; bicyclo[2.2.1]heptane-2-yl; 1-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; 3-methylbutyl; (tetrahydro-2H-pyran-4-yl)ethyl; 4-(methyl(sulfanyl))butyl; 3,7-dimethyl-7-methoxyoctyl; (tetrahydro-2H-thiopyran-4-yl)ethyl; cyclohexyl; cycloheptyl; cyclopentyl; (N,N-dimethylaminocarbonyl)piperidine-4-yl; N-acetylpiperidine-4-yl; 1-(cyclopropyl(carbonyl))piperidine-4-yl; (prop-2-ynoxy(carbonyl))piperidine-4-yl; piperidine-4-yl; propoxycarbonylpiperidine-4-yl; (prop-2-enoxy(carbonyl))piperidine-4-yl; (morpholine-4-yl(carbonyl))piperidine-4-yl; and 1-methoxycarbonylpiperidine-4-yl; bicyclo[2.2.1]hept-5-en-2-ylmethyl; and isopropylcarbonylpiperidine-4-yl.
  • 2. X1, X2, X3, and X4 Groups
  • X1 is —NR3A—, and X2 is —CR′3BR′3C—; wherein each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB)—, —P(O)(ORB)NRB— or —NRBSO2NRB—; each R6 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or one of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic ring or an optionally substituted 3-10 membered heterocycloaliphatic ring.
  • X3 is —CR4AR4B—, and X4 is —CR′4CR′4B—; wherein each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—; each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R4A and R4B together with the carbon atom to which they are attached form a carbonyl group.
  • In some embodiments, X1 is —NR3A— and X2 is —CR′3AR′3B—. For example, X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein R3B and R3C together with the carbon atom to which they are attached form a carbonyl group. In another example, X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C is hydrogen.
  • In several embodiments, X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is independently a bond, or an independently and optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of Z are optionally and independently replaced by —CO—, —CONRB—, —CO2—, —NRBCO2—, —SO2—, —O—, or —NRBCO—, R6 is RB, and each RB is hydrogen or optionally substituted C1-3 aliphatic. For example, X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is —CO—, —CONH—, —CO2—, —NHCO2—, —SO2—, —O—, or —NHCO—, and R6 is hydrogen or optionally substituted C1-3 aliphatic. In other examples, X1 is —NR3A—, wherein R3A is ZBR6, ZB is —CO— or —CONH—, and R 6 is hydrogen or optionally substituted C1-3 aliphatic.
  • In several embodiments, X2 is —CR′3BR′3C—, wherein R′3B and R′3C are each hydrogen, or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
  • In other embodiments, X1 is —NR3A—, wherein R3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C are hydrogen or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
  • In other embodiments, X3 is —CR4AR4B, wherein R4A and R4B together with the carbon atom to which they are attached form a carbonyl group, or each of R4A and R4B is hydrogen.
  • In several embodiments, X4 is —CR′4AR′4B—, wherein each of R′4A and R′4B are hydrogen.
  • 3. R2 Group
  • Each R2 is independently -ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA—; each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R2 and one of R3A or R3B together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic or carbocyclic ring.
  • In several embodiments, each R2 is hydrogen or optionally substituted C1-6 aliphatic. For example, R2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
  • In other embodiments, each R2 is hydrogen.
  • 4. m, n, and q groups
  • m is 1-3.
  • n is 1-3.
  • q is 0-4.
  • In several embodiments, m is 1, 2, or 3.
  • In other embodiments, n is 1, 2, or 3. For example, m+n is 4. In another example, m and n are 2.
  • In some embodiments, q is 0, 1, 2, 3, or 4. For example, q is 0 or 4.
  • C. Subgeneric Methods
  • Another aspect of the present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I-A:
  • Figure US20080113958A1-20080515-C00003
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, m, n, and q are define above in formula I.
  • Another aspect of the present invention provides methods of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I-B:
  • Figure US20080113958A1-20080515-C00004
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, m, n, and q are define above in formula I.
    • III. Compounds
  • A. Generic Description
  • The present invention provides a compound of formula I:
  • Figure US20080113958A1-20080515-C00005
  • a pharmaceutically acceptable salt thereof, wherein
  • X1 is —NR3A—;
  • X2 is —CR′3BR′3C—;
  • X3 is —CR4AR4B—;
  • X4 is —CR′4CR′4B—;
  • R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
  • Each R2 is independently ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA,
      • Each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic or carbocyclic ring,
  • Each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB)—, —P(O)(ORB)NRB— or —NRBSO2NRB—,
      • Each R6 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or
        • One of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic or an optionally substituted 3-10 membered heterocycloaliphatic;
  • Each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—,
      • Each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
      • Each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
        • R4A and R4B together with the carbon atom to which they are attached form a carbonyl group;
  • m is 1-3;
  • n is 1-3; and
  • q is 0-4.
  • B. Specific Description
  • 1. Substituent R1
  • R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic.
  • In some embodiments, R1 is -ZDR8, wherein each ZD is independently a bond or an optionally substituted branched or straight C1-12 aliphatic chain wherein up to two carbon units of ZD are optionally and independently replaced by —CO—, —CS—, —CONRD—, —CONRDNRDND—, —CO2—, —OCO—, —NRDCO2—, —O—, —NRDCONRD—, —OCONRD—, —NRDNRD—, —NRDCO—, —S—, —SO—, —SO2—, —NRD—, —SO2NRD—, —NRDSO2—, or —NRDSO2NRD—. Each R8 is independently RD, halo, —OH, —NH2, —NO2, —CN, or —OCF3. Each RD is independently hydrogen or an optionally substituted aliphatic, an optionally substituted cycloaliphatic, or an optionally substituted heterocycloaliphatic.
  • In some embodiments, R1 is an optionally substituted C1-12 aliphatic. In another embodiment, R1 is an optionally substituted group selected from C1-12 alkyl, C1-12 alkenyl, or C1-12 alkynyl. In yet another embodiment, R1 is an optionally substituted C1-6 alkyl. In several examples, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted with a cycloaliphatic, a heterocycloaliphatic, an alkylsulfanyl, an alkoxy, an amino, or combinations thereof, where each of which is optionally substituted.
  • In some embodiments, R1 is an optionally substituted cycloaliphatic. In several examples, R1 is an optionally substituted group selected from a monocyclic cycloaliphatic or a bicyclic cycloaliphatic. In another example, R1 is an optionally substituted group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, alkoxycarbonyl, cycloaliphatic, or combinations thereof.
  • In some embodiments, R1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic. In several examples, R1 is an optionally substituted group selected from 7-10 membered bicyclic cycloalkyl or 7-10 membered bicyclic cycloalkenyl. In another examples, R1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, bicyclo[2.2.2]oct-2-ene-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • In some embodiments, R1 is an optionally substituted group selected from monocyclic heterocycloaliphatic or a bicyclic heterocycloaliphatic. In some examples, R1 is an optionally substituted 3-8 membered monocyclic cycloaliphatic having 1-3 heteroatoms selected from N, O, and S. In another examples, R1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
  • In some embodiments, R1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms selected from N, O, and S. In several examples, R1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic. In another examples, R1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted with 1-3 of halo, aliphatic, hydroxy, amino, acyl, or combinations thereof.
  • In several alternative embodiments, R1 is one selected from: hydrogen; cyclohexylmethyl; 3,3-dimethylbutyl; bicyclo[2.2.1]hept-5-en-2-yl; cyclohept-1-yl; bicyclo[2.2.1]heptane-2-yl; 1-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; 3-methylbutyl; (tetrahydro-2H-pyran-4-yl)ethyl; 4-(methyl(sulfanyl))butyl; 3,7-dimethyl-7-methoxyoctyl; (tetrahydro-2H-thiopyran-4-yl)ethyl; cyclohexyl; cycloheptyl; cyclopentyl; (N,N-dimethylaminocarbonyl)piperidine-4-yl; N-acetylpiperidine-4-yl; 1-(cyclopropyl(carbonyl))piperidine-4-yl; (prop-2-ynoxy(carbonyl))piperidine-4-yl; piperidine-4-yl; propoxycarbonylpiperidine-4-yl; (prop-2-enoxy(carbonyl))piperidine-4-yl; (morpholine-4-yl(carbonyl))piperidine-4-yl; and 1-methoxycarbonylpiperidine-4-yl; bicyclo[2.2.1]hept-5-en-2-ylmethyl; and isopropylcarbonylpiperidine-4-yl.
  • 2. X1, X2, X3, and X4 Groups
  • X1 is —NR3A—, and X2 is —CR′3BR′3C—; wherein each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB)—, —P(O)(ORB)NRB— or —NRBSO2NRB—; each R5 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic, or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or one of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic ring or an optionally substituted 3-10 membered heterocycloaliphatic ring.
  • X3 is —CR4AR4B—, and X4 is —CR′4CR′4B—; wherein each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—; each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R4A and R4B together with the carbon atom to which they are attached form a carbonyl group.
  • In some embodiments, X1 is —NR3A— and X2 is —CR′3AR′3B—. For example, X1 is —NR3A— and
  • X2 is —CR′3BR′3C—, wherein R3B and R3C together with the carbon atom to which they are attached form a carbonyl group. In another example, X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C is hydrogen.
  • In several embodiments, X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is independently a bond, or an independently and optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CONRB—, —CO2—, —NRBCO2—, —SO2—, —O—, or —NRBCO—, R6 is RB, and each RB is hydrogen or optionally substituted C1-3 aliphatic. For example, X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is —CO—, —CONH—, —CO2—, —NHCO2—, —SO2—, —O—, or —NHCO—, and R6 is hydrogen or optionally substituted C1-3 aliphatic. In other examples, X1 is —NR3A—, wherein R3A is ZBR6, ZB is —CO— or —CONH—, and R6 is hydrogen or optionally substituted C1-3 aliphatic.
  • In several embodiments, X2 is —CR′3BR′3C—, wherein R′3B and R′3C are each hydrogen, or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
  • In other embodiments, X1 is —NR3A—, wherein R3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C are hydrogen or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
  • In other embodiments, X3 is —CR4AR4B, wherein R4A and R4B together with the carbon atom to which they are attached form a carbonyl group, or each of R4A and R4B is hydrogen.
  • In several embodiments, X4 is —CR′4AR′4B—, wherein each of R′4A and R′4B are hydrogen.
  • 3. R2 Group
  • Each R2 is independently -ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA, —OCONRA, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA—; each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl. Alternatively, R2 and one of R3A or R3B together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic or carbocyclic ring.
  • In several embodiments, R2 is hydrogen or optionally substituted C1-6 aliphatic. For example, R2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
  • 4. m n and q groups
  • m is 1-3.
  • n is 1-3.
  • q is 0-4.
  • In several embodiments, m is 1, 2, or 3.
  • In other embodiments, n is 1, 2, or 3. For example, m+n is 4. In another example, m and n are 2.
  • In some embodiments, q is 0, 1, 2, 3, or 4. For example, q is 0 or 4.
  • C. Subgeneric Compounds
  • Another aspect of the present invention provides compounds useful for modulating the activity of a muscarinic receptor according to formula I-A:
  • Figure US20080113958A1-20080515-C00006
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, m, n, and q are define above in formula I.
  • Another aspect of the present invention provides compounds useful for modulating the activity of a muscarinic receptor according to formula I-B:
  • Figure US20080113958A1-20080515-C00007
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, m, n, and q are define above in formula I.
    • IV. Combinations of Embodiments
  • Other embodiments include any combination of the aforementioned substituents R1, R2, X1, X2, X3, X4, m, n, q, and other variables contained therein.
    • V. Exemplary Compounds
  • Specific exemplary compounds of formulae (I, I-A, and I-B) are shown below in Table 1.
  • TABLE 1
    Exemplary compounds of formulae (I, I-A, and I-B).
    Figure US20080113958A1-20080515-C00008
    Figure US20080113958A1-20080515-C00009
    Figure US20080113958A1-20080515-C00010
    Figure US20080113958A1-20080515-C00011
    Figure US20080113958A1-20080515-C00012
    Figure US20080113958A1-20080515-C00013
    Figure US20080113958A1-20080515-C00014
    Figure US20080113958A1-20080515-C00015
    Figure US20080113958A1-20080515-C00016
    Figure US20080113958A1-20080515-C00017
    Figure US20080113958A1-20080515-C00018
    Figure US20080113958A1-20080515-C00019
    Figure US20080113958A1-20080515-C00020
    Figure US20080113958A1-20080515-C00021
    Figure US20080113958A1-20080515-C00022
    Figure US20080113958A1-20080515-C00023
    Figure US20080113958A1-20080515-C00024
    Figure US20080113958A1-20080515-C00025
    Figure US20080113958A1-20080515-C00026
    Figure US20080113958A1-20080515-C00027
    Figure US20080113958A1-20080515-C00028
    Figure US20080113958A1-20080515-C00029
    Figure US20080113958A1-20080515-C00030
    Figure US20080113958A1-20080515-C00031
    Figure US20080113958A1-20080515-C00032
    Figure US20080113958A1-20080515-C00033
    Figure US20080113958A1-20080515-C00034
    Figure US20080113958A1-20080515-C00035
    Figure US20080113958A1-20080515-C00036
    Figure US20080113958A1-20080515-C00037
    Figure US20080113958A1-20080515-C00038
    Figure US20080113958A1-20080515-C00039
    Figure US20080113958A1-20080515-C00040
    Figure US20080113958A1-20080515-C00041
    Figure US20080113958A1-20080515-C00042
    Figure US20080113958A1-20080515-C00043
    • VI. Formulations, Administrations, and Uses
  • The present invention includes within its scope pharmaceutically acceptable prodrugs of the compounds of the present invention. A “pharmaceutically acceptable prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of the present invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention or an active metabolite or residue thereof. Preferred prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal or which enhance delivery of the parent compound to a biological compartment relative to the parent species.
  • The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+ (C1-4 alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • The pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • The pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • For ophthalmic use, the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • Most preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration.
  • The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the modulator can be administered to a patient receiving these compositions.
  • It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • Depending upon the particular condition, or disease, to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”
  • According to a preferred embodiment, the compounds of formulae (I, I-A, and I-B) are selective modulators of M1, M2 and M4. More preferably, the compounds of formulae (I, I-A, and I-B) are effective modulators of M1 and/or M4. Yet more preferably, certain compounds of formulae (I, I-A, I-B) are selective modulators of M1. Or, preferably, certain compounds of formulae (I, I-A, and I-B) are selective modulators of M4.
  • Applicants believe that the ability of the compounds of the present invention to modulate the activity of muscarinic receptors is derived from the affinity of these compounds to the muscarinic receptors. Such affinity, applicants believe, activates a muscarinic receptor (i.e., an agonist) or inhibits the activity of a muscarinic receptor.
  • The term “selective” as used herein means a measurably greater ability to modulate one muscarinic receptor subtype when compared to the other muscarinic receptor subtypes. E.g., the term “selective M4 agonist” means a compound that has a measurably greater ability to act as an M4 agonist when compared to that compound's agonist activity with the other muscarinic receptor subtype(s).
  • According to an alternative embodiment, the present invention provides a method of treating a muscarinic receptor mediated disease in a mammal, such as a human, including the step of administering to said mammal a composition comprising a compound of formulae (I, I-A, and I-B) or an embodiment thereof as set forth herein.
  • According to another embodiment, the present invention provides a method of treating a disease mediated by a muscarinic receptor including the step of administering to said mammal a composition comprising a compound of formulae (I, I-A, and I-B), or other embodiments thereof as set forth above. Preferably, said disease is mediated by M1, or said disease is mediated by M4.
  • According to yet another embodiment, the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, sudden infant death syndrome, Parkinson's disease, peripheral disorders such as reduction of intra ocular-pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, wherein said method comprises the step of contacting said patient with a compound according to the present invention.
  • According to an alternative embodiment, the present invention provides a method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from pain, psychosis (including schizophrenia, hallucinations, and delusions), Alzheimer's disease, Parkinson's disease, glaucoma, bradycardia, gastric acid secretion, asthma, or GI disturbances.
  • According to a preferred embodiment, the present invention is useful for treating or reducing the severity of psychosis, Alzheimer's disease, pain, or Parkinson's disease.
  • All references cited within this document are incorporated herein by reference.
    • VII. Preparations and Examples
  • In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
  • Figure US20080113958A1-20080515-C00044
  • A mixture of tert-butyl 4-oxo-3,4-dihydro-2H-spiro[naphthalene-1,4′-piperidine]-1′-carboxylate A (1.24 g, 3.93 mmol), hydroxylamine hydrochloride (1.37 g, 19.7 mmol) and sodium acetate trihydrate (3.20 g, 23.5 mmol) in ethanol (50 ml) was heated under reflux for 20 h. The reaction was concentrated and the residue was suspended in water, extracted with dichloromethane (3×). The combined extracts were dried over Na2SO4 and concentrated to give tert-butyl 4-(hydroxyimino)-3,4-dihydro-2H-spiro[naphthalene-1,4′-piperidine]-1′-carboxylate B (1.32 g). LC-MS: m/e=331.1 (M+H, 100%), 275.0 (M+H−C(CH3)3). Rt=3.35 min. 1H-NMR (500 MHz, CDCl3): 8.01 (d, 0.25H), 7.93 (d, 0.75H), 7.41-7.34 (m, 2H), 7.23-7.19 (m, 1H), 3.95-3.92 (m, 2H), 3.04-2.96 (m, 2H), 2.87 (t, 0.5H), 2.82 (t, 1.5H), 2.3 (br. s, 1H), 1.93-1.84 (m, 4H), 1.54-1.52 (d, 2H), 1.43 (s, 9H).
  • At 0° C., 6N NaOH (4 ml, 2.4 mmol) was added to a solution of the hydroxyimine B (1.32 g, 4 mmol) and tosyl chloride (840 mg, 4.42 mmol) in acetone (30 ml) and kept at room temperature for 3 h. The reaction mixture was poured into ice, extracted with EtOAc, dried over Na2SO4, concentrated and purified on silica gel (hexane/EtOAc 9:1 to 7:3) to give tert-butyl 4-(tosyloxyimino)-3,4-dihydro-2H-spiro[naphthalene-1,4′-piperidine]-1′-carboxylate C (1.66 g) in 85% yield as a white solid. LC-MS: m/e=485.1 (M+H), 257.1 (M+H−OTs−C(CH3)3, 100%). Rt=4.01 min.
  • At −78° C., aluminum chloride (1.7 g, 12.7 mmol) was added to a solution of the tosyloxyimine C (1.66 g, 3.43 mmol) in dichloromethane (20 ml) under nitrogen. After the addition, the cooling bath was removed and the reaction mixture was kept at room temperature for 1.5 h. The reaction mixture was cooled with a dry ice-acetone bath, treated with 50% NaOH to pH 11, extracted with dichloromethane (monitored by HPLC). The combined extracts were concentrated and treated with Boc2O (1 g) and triethylamine (3 ml) for 1 h. The mixture was concentrated and purified by flash column chromatography (hexane/EtOAc 8:2 to 7:3) to give tert-butyl 2-oxo-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate D (830 mg) in a 73% yield. LC-MS: m/e=331.0 (M+H), 275.0 (M+H−C(CH3)3, 100%). Rt=2.79 min. 1H-NMR (500 MHz, DMSO-d6): 9.51 (s, 1H), 7.37 (d, 1H), 7.24 (t, 1H), 7.14 (t, 1H), 6.99 (d, 1H), 3.33 (m, 4H), 2.14-2.10 (m, 4H), 2.10 (dd, J=5.1, 11.3 Hz, H), 1.94-1.89 (m, 2H), 1.86-1.81 (m, 2H), 1.40 (s, 9H). 1H NMR (500 MHz, CDCl3): 7.41 (dd, 1H), 7.37 (t, 1H), 7.32 (t, 1H), 7.19 (s, 1H), 6.97 (dd, 1H), 3.54-3.49 (m, 2H), 3.43 (ddd, 2H), 2.38 (t, 2H), 2.21 (t, 2H), 2.10 (ddd, 2H), 1.98-1.94 (m, 2H), 1.46 (s, 9H).
  • A solution of the Boc-protected benzoazepine (200 mg) in dichloromethane (3 ml) was treated with trifluoroacetic acid (1 ml) for 1 h. The reaction mixture was concentrated, co-evaporated with acetonitrile and dissolved in dichloromethane. The resulting solution was washed with a mixture of brine (ca. 20 ml) and 6N NaOH (1 ml), dried over Na2SO4 and concentrated to give 3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one E (139 mg) as a white solid. LC-MS: m/e=231.0 (M+H, 100%). Rt=0.79 min.
  • Figure US20080113958A1-20080515-C00045
  • A solution of the 2-oxo-benzo[b]azepine D (560 mg, 1.71 mmol) in THF (20 ml) was heated under reflux with borane-tetrahydrofuran complex (1.0M in THF, 25 ml) for 3 h. Additional borane-tetrahydrofuran complex (11.0M in THF, 10 ml) was added and heated for another 2 h. The reaction mixture was diluted with dichloromethane, washed with 0.5 N HCl (caution! Hydrogen gas was released.). The aqueous phase was basified with 6N NaOH, extracted with dichloromethane. The organic phase was dried (Na2SO4) concentrated and purified by flash column chromatography (CH2Cl2) to give tert-butyl 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate F (520 mg) as a colorless oil. LC-MS: m/e=261.0 (M+H−C(CH3)3, 100%). Rt=3.05 min. 1H-NMR (500 MHz, DMSO-d6): 7.15 (d, 1H), 6.95 (t, 1H), 6.84 (d, 1H), 6.77 (t, 1H), 4.94 (br. s, 1H), 3.47-3.40 (m, 2H), 3.25 (m, 2H), 2.87 (br. s, 2H), 1.97 (m, 2H), 1.89-1.84 (m, 2H), 1.73 (m, 2H), 1.67-1.65 (m, 2H), 1.40 (s, 9H), 2-1.26 (m, 9H).
  • The dimethylcarbamate J (see below) failed to be synthesized by the treatment with dimethylcarbamyl chloride (1.5-4 equivalent) with the azepine F (180 mg) in the presence of Hunig's base (3 equivalent) or sodium hydride (3 equivalent) under reflux in THF and HMPA. The mixture was treated with acetyl chloride (0.14 ml, 1 mmol) to give tert-butyl 1-acetyl-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate G (257 mg, crude). LC-MS: m/e=359.1 (M+H, 100%), 303.1 (M+H−C(CH3)3). Rt=3.27 min. 1H NMR (500 MHz, CDCl3): 7.32 (d, 1H), 7.26 (td, 1H), 7.2 (m, 1H), 7.02 (dd, 1H), 4.67 (br. d, 1H), 3.85-3.82 (m, 1H), 3.38-3.31 (m, H). 3.09 (s, H), 3.05 (d, J=2.8 Hz, H), 2.99 (s, H), 2.92 (d, J=9.0 Hz, H), 2.84 (s, H), 2.77 (s, H), 2.67 (dd, J=2.4, 9.7 Hz, H), 2.59 (s, H), 2.56 (s, H), 2.52 (d, J=11.7 Hz, H), 2.23 (s, H), 2.20-2.14 (m, H), 2.09-2.02 (m, H), 1.93-1.90 (m, H), 1.85 (d, J=2.3 Hz, H), 1.63 (s, H), 1.60-1.55 (m, H), 1.42 (s, H), 1.39-1.35 (m, H), 1.32 (s, H), 1.30 (s, H), 1.19 (s, H),
  • A solution of the Boc-protected piperidine G (257 mg) in dichloromethane (5 ml) was treated with TFA (1 ml) to give 1-(3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidine]-1(2H)-yl)ethanone (180 mg) after workup as for the conversion of compound D to E. LC-MS: m/e=259.0 (M+H)3, 100%). Rt=1.35 min.
  • Figure US20080113958A1-20080515-C00046
  • At 0° C., a solution of diphosgene (340 mg, 1.71 mmol) in dichloromethane (5 ml) was added to a solution of the azepine F (415 mg, 1.31 mmol) and ethyldiisopropylamine (0.6 ml, 3.44 mmol). After addition, the reaction mixture was kept at room temperature for 3 hours. The reaction mixture was equally divided into two parts.
  • One portion was treated with 2.0M dimethylamine in THF (5 ml, 10 mmol) overnight (15 h). After evaporation, the residue was dissolved in dichloromethane, washed with brine. The organic phase was dried and concentrated to give tert-butyl 1-(dimethylcarbamoyl)-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate J (crude, 278 mg). LC-MS: m/e=338.1 (M+1), 332.1 (M+H−C(CH3)3, 100%). Rt=3.50 min. The Boc-protected N,N-dimethyl carboxamide J (278 mg) was treated with TFA (1 ml) in dichloromethane (5 ml) for 1 h and workup as for the preparation of H, N,N-dimethyl-3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidine]-1(2H)-carboxamide K (169 mg) was obtained as a white solid. LC-MS: m/e=288.1 (M+1, 100%). Rt=1.39 min
  • A second portion was dissolved in MeOH (10 ml) and ammonia gas was bubbled through for 10 min. The reaction mixture was stirred for 3 h. Workup as above to give tert-butyl 1-carbamoyl-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate L (crude, 480 mg). LC-MS: m/e=360.1 (M+1), 304.0 (M+H−C(CH3)3, 100%). Rt=2.88 min. Treatment of the Boc-protected carboxamide L (480 mg) with TFA (1 ml) in dichloromethane (5 ml) for 1 h and workup as for the preparation of H from 7, 3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidine]-1(2H)-carboxamide M (270 mg) was obtained as a white solid. LC-MS: m/e=260.1 (M+1, 100%). Rt=1.02 min
  • Figure US20080113958A1-20080515-C00047
  • To a solution of tert-butyl 2-oxo-1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4′-piperidine]-1′-carboxylate D (0.51 g, 1.54 mmol) in DMF at 0° C. was added NaH (60% dispersion in hexanes (130 mg, 3.2 mmol, 2 eq) followed by MeI (0.19 mL, 3.0 mmol, 2 eq). The reaction was warmed to RT and stirred for 3 d. The reaction was diluted with EtOAc and washed with 50% NaHCO3 (2×) and brine. The organics were dried over Na2SO4, filtered and evaporated to give a yellow oil (595 mg) which was used directly in the next step.
  • The crude product (1.54 mmol) was dissolved in CH2Cl2 and TFA was added and the reaction was stirred at RT for 2 h. The solvent was removed in vacuo and the product azeotroped with CH2Cl2 (3×). The product was dissolved in CH2Cl2 and washed with 1N NaOH, to afford upon drying 0 as a yellow oil (0.463 g, quantitative). FIA m/e=245.4
  • Reductive Amination
  • Figure US20080113958A1-20080515-C00048
  • A solution of 3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one E (20 mg) and 3,3-dimethylbutanal (20 mg) in 1,2-dichloroethane (2 ml) was stirred at 40° C. for 3 h, treated with sodium triacetoxyborohydride (55 mg) for 1 h, cooled to room temperature and MeOH (1 ml) and acetic acid (0.1 ml) was added and stirred for 1 h. After evaporation, the residue was dissolved in MeOH (1 ml) and purified by reverse phase HPLC to give 1′-(3,3-dimethylbutyl)-3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one 36 as a TFA salt. LC-MS: m/e=315.1 (M+H, 100%). Rt=1.61 min.
  • Figure US20080113958A1-20080515-C00049
  • To a solution of 3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one E (800 mg, 3.47 mmol) and cycloheptanone (1.12 g, 10 mmol) in 1,2-dichloroethane (25 ml) was added titanium tetraisopropoxide (2.5 ml, 8.8 mmol) and the resulting solution was stirred at 40° C. for 15 h, treated with sodium triacetoxyborohydride (2.12 g, 10 mmol) for 1 h, cooled to room temperature and MeOH (1 ml) was added and stirred for 1 h. After evaporation, the residue was dissolved in dichloromethane, washed with a mixture of brine and 6N NaOH (3 ml). The aqueous phase (suspension) was extracted with dichloromethane (3×). The extracts were dried over Na2SO4, concentrated and purified by silica gel chromatography (CH2Cl2/MeOH 9:1 to 8:2) to give 1′-cycloheptyl-3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one (800 mg). LC-MS: m/e=327.1 (M+H, 100%). Rt=1.57 min. 1H-NMR (500 MHz, DMSO (d6)): 9.46 (s, 1H), 7.37 (d, 1H), 7.20 (t, 1H), 7.12 (t, 1H), 6.95 (d, 1H), 2.51 (m, 2H), 2.44-2.35 (m, 3H), 2.08 (t, 2H), 2.01 (t, 2H), 1.94 (m, 2H), 1.86 (m, 2H), 1.66 (m, 2H), 1.58 (m, 2H), 1.49-1.39 (m, 6H), 1.35-1.29 (m, 2H). The above product was suspended in water, filtration and the solid was dissolved in a diluted 1N HCl (6 ml), lyophilized to give a HCl salt 24 (723 mg). Two conformers were observed with ca. 1:2 ratios. 1H-NMR (500 MHz, DMSO-d6): 10.03 (m, 1H); 9.61, 9.57 (2s, 1H); 7.42 (d, 0.35H), 7.38 (d, 0.65H); 7.31, 7.26 (2t, 1H); 7.21, 7.16 (2t, 1H); 7.05, 7.01 (2t, 1H); 3.29 (d, 2H), 3.21 (q, 2H), 2.73 (d, 0.7H), 2.28 (d, 1.3H), 2.63-2.57 (m, 1H), 2.22-1.98 (m, 8H), 1.89-1.84 (m, 1H), 1.73-1.60 (m, 3H), 1.55-1.33 (m, 7H).
  • Figure US20080113958A1-20080515-C00050
  • A solution of 1-methyl-3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one O 60 mg) and bicyclo[3.2.1.]octan-3-one (20 mg) in 1,2-dichloroethane (3 ml) was, treated with sodium triacetoxyborohydride (110 mg, 0.52 mmol) and titanium tetraisopropoxide (0.16 mL, 0.54 mmol) and the reaction was stirred at RT for 5 d. MeOH (1 ml) and 1N NaOH (0.5 ml) were added and the reaction was stirred for 1 h. The mixture was diluted with EtOAc (5 mL) and centrifuged. The organics were decanted, evaporated, then the residue was dissolved in MeOH (1 ml) and purified by reverse phase HPLC to give 1′-(bicyclo[3.2.1.]octan-3-yl)-1-methyl-3,4-dihydrospiro[benzo[b]azepine-5,4′-piperidin]-2(1H)-one (19) as a TFA salt. LC-MS: m/e=426.4 (M+H). Rt=1.9 min.
  • Table 2 below illustrates synthetic methods used to produce exemplary compounds of formula I.
  • TABLE 2
    Methods used to produce exemplary compounds of formula I.
    Comp No. Preparation method
    1 II
    3 II
    4 II
    5 I
    12 II
    18 II
    19 III
    21 II
    24 II
    29 II
    30 III
    35 II
    36 I
  • Analytical data for selected compounds of the present invention is shown below in Table 3.
  • TABLE 3
    LCMS LC RT
    Comp No. M + 1 (min)
    1 325. 1.46
    2 366.2 1.61
    3 329.5 2.3
    4 412.2 1.53
    5 337.1 1.61
    6 356.3 1.61
    7 355.2 1.76
    8 415.2 1.61
    9 365.2 1.72
    10 469.3 1.72
    11 384.3 1.79
    12 341.5 2.37
    13 344.1 1.61
    14 414.3 1.57
    15 394.2 1.77
    16 368.2 1.65
    17 353.2 1.61
    18 386.1 1.46
    19 353.4 1.9
    20 356.2 1.65
    21 400.4 2.2
    22 441.3 1.58
    23 443.2 1.65
    24 327.1 1.57
    25 396.3 1.83
    26 354.2 1.5
    27 384.2 1.81
    28 440.2 1.65
    29 339.1 1.61
    30 426.4 1.95
    31 372.3 1.79
    32 343.1 1.74
    33 382.3 1.68
    34 329.1 1.64
    35 339.5 2.3
    36 315.1 1.61
    • VIII. Assays for Detecting and Measuring Inhibition Properties of Compounds Functional Mobilization of Intracellular Calcium to Determine Muscarinic Receptor Activity:
  • CHO cells expressing muscarinic receptors (M1 to M5) are grown as monolayers in tissue culture flasks at 37° C. in a humidified atmosphere containing 5% CO2 and passaged every 3-5 days. The growth media is Dulbecco's modified eagles medium (DMEM, Gibco Cat# 12430-054), containing 25 mM Hepes and supplemented with Fetal Bovine Serum (Hyclone, Cat# SH30071.03), 0.1 mM of MEM non-essential amino acids (GIBCO, Cat# 11140-050), 1 mM MEM Sodium Pyruvate (GIBCO Cat# 11360-070) and 100 units/ml of Penicillin G and 100 μg/ml of Streptomycin (GIBCO Cat# 15140-122). The recombinant muscarinic receptor cell lines are grown under antibiotic pressure with media containing 25 μg/ml zeocin and 500 μg/ml G418 (MI-CHO), 4 μg/ml puromycin, 50 μg/ml zeocin and 2.5 μg/ml blasticidin (M2 and M4-CHO) or 50 μg/ml zeocin and 4 μg/ml puromycin (M3 and M5-CHO).
  • Cells are harvested at 80-90% confluence using Versene (GIBCO Cat# 15040-066), collected by centrifugation and seeded 18-24 hours prior to running the calcium assay at a density of 5,000-10,000 cells/well in back-walled, clear-bottomed 384-well plates (BD Biocoat, poly-D-lysine, Cat#356663). The day of the experiment, the cells are washed with a plate washer (Bioteck Instruments, ELX 405) using bath 1 buffer (140-mM NaCl, 4.5-mM KCl, 2-mM CaCl2, 1-mM MgCl2, 10-mM Hepes-Na, 10-mM Glucose, pH 7.4, with NaOH) containing 1 mM Probenecid. Next, the calcium dye Fluo-3 (25 μl well of Fluo-3 AM at 4 μM, Molecular Probes F-1241, in Bath 1 buffer containing 1 mM Probenecid) is added to the 25 μl of Bath 1 remaining in each well after the plate wash and the dye is loaded at 37° C. in the tissue culture incubator for 60-90 min. The fluorescent dye is removed using the plate washer with Bath 1 containing 1 mM Probenecid, leaving 25 μl/well of this solution after the wash. Alternatively, cells can be loaded with the calcium indicator from Molecular Devices (Calcium 3 Assay Reagents, Cat # R7181) adding 5 μl of a 5× solution dye in Bath 1 containing 1 mM Probenecid (10 ml per dye flask cat# R7182 to generate a solution 20×) to 20 μl of the same buffer. After loading for 60 min, the experiment can be run without having to remove the dye.
  • Compounds are prepared at a 2× fold concentration in a 96-well plate (round bottom, Costar Corning cat# 3656), by reconstituting the pre-spotted compounds in bath 1 containing 1 mM probenecid. The final concentration DMSO is 0.5%, and the amount of DMSO is normalized across the assay plate. To determine an agonist action of the compounds on muscarinic receptors, the reconstituted compounds are added (25 μl compound/well) to the cell assay plate (containing 25 μl/well) using the multi-channel robotic system of the FLIPR 3 Instrument (Molecular Devices, Sunnyvale, Calif.). To determine a functional inhibitory action of the compounds on muscarinic receptors, the reconstituted compounds are added (25 μl compound/well) to the assay plate and pre-incubated for 15 min prior to adding 25 μl of Carbachol at 3× the EC80 for each muscarinic subtype. Alternatively, the compounds can be co-applied simultaneously with the agonist. In both assay modes, the fluorescence is recorded for 60 sec (excitation wavelength is 488 nM and emission wavelength 540 nm) using the FLIPR 3 instrument.
  • The potency, efficacy and selectivity of the muscarinic compounds were evaluated by screening the compound activity across the whole family (M1 to M5 cells). Compounds were also screened for activity on other proteins such as other GPCRs and ion channels to determine selectivity on M4 receptors.
  • The compounds of the present invention were found to modulate the M1 and/or M4 muscarinic receptors selectively over the other receptor types.
  • Examples of activities and efficacies of the muscarinic compounds of formulae (I, I-A, and I-B) on modulating M1 and M4 receptors are shown below in Table 4. The compound activity for the M1 and M4 is illustrated with “+++” if activity was measured to be less than 2.0 μM, “++” if activity was measured to be from 2.0 μM to 10.0 μM, “+” if activity was measured to be greater than 10.0 μM, and “−” if no data was available. The efficacy for M1 and M4 modulation is illustrated with “+++” if efficacy was calculated to be greater than 100%, “++” if efficacy was calculated to be from 100% to 25%, “+” if efficacy was calculated to be less than 25%, and “−” if no data was available. It should be noted that 100% efficacy is the maximum response obtained with the Carbachol control.
  • TABLE 4
    Activities and efficacies of compounds of formulae (I, I-A, and I-B).
    Comp M1 M4 M1 M4
    No. Activity Activity Efficacy Efficacy
    1 +++ +++ +++ ++
    2 ++ +++ + ++
    3 ++ +++ ++ ++
    4 +++ +++ ++ ++
    5 ++ +++ ++ ++
    6 + + + +
    7 + ++ + +
    8 +++ ++ ++ ++
    9 + +++ + ++
    10 + ++ + +
    11 + + + +
    12 ++ +++ ++ ++
    13 ++ +++ ++ ++
    14 +++ +++ ++ ++
    15 + +++ + ++
    16 ++ +++ ++ ++
    17 + + + +
    18 +++ +++ ++ ++
    19 +++ +++ ++ ++
    20 + ++ + +
    21 ++ ++ ++ ++
    22 +++ +++ ++ ++
    23 ++ +++ ++ ++
    24 +++ +++ ++ ++
    25 + +++ + ++
    26 + + + +
    27 + + + +
    28 +++ +++ ++ ++
    29 +++ +++ ++ ++
    30 +++ +++ ++ ++
    31 + +++ + ++
    32 ++ +++ + ++
    33 + + + +
    34 + + + +
    35 + +++ + ++
    36 +++ +++ ++ ++
    • OTHER EMBODIMENTS
  • It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (73)

1. A method of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound of formula I:
Figure US20080113958A1-20080515-C00051
a pharmaceutically acceptable salt thereof, wherein
X1 is —NR3A—;
X2 is —CR′3BR′3C—;
X3 is —CR4AR4B—;
X4 is —CR′4CR′4B—;
R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
Each R2 is independently -ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA, —CONRANRA—, —CO2, —OCO—, —NRACO2—, —O—, —NRACONRA, —OCONRA, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA—,
Each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic or carbocyclic ring,
Figure US20080113958A1-20080515-C00052
Figure US20080113958A1-20080515-C00053
Figure US20080113958A1-20080515-C00054
Figure US20080113958A1-20080515-C00055
Each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB)—, —P(O)(ORB)NRB— or —NRBSO2NRB—,
Each R6 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or
One of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic or an optionally substituted 3-10 membered heterocycloaliphatic;
Each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—,
Each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R4A and R4B together with the carbon atom to which they are attached form a carbonyl group;
m is 1-3;
n is 1-3; and
q is 0-4.
2. The method of claim 1, wherein X1 is —NR3A— and X2 is —CR′3AR′3B—.
3. The method of claim 2, wherein X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein R3B and R3C together with the carbon atom to which they are attached form a carbonyl group.
4. The method of claim 3, wherein X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C is hydrogen.
5. The method of claim 1, wherein X3 is —CR4AR4B, wherein R4A and R4B together with the carbon atom to which they are attached form a carbonyl group, or each of R4A and R4B is hydrogen.
6. The method of claim 1, wherein X4 is —CR′4AR′4B, and each of R4A and R4B are hydrogen.
7. The method of claim 1, wherein R1 is an optionally substituted C1-12 aliphatic.
8. The method of claim 7, wherein R1 is an optionally substituted group selected from C1-12 alkyl, C1-12 alkenyl, or C1-12 alkynyl.
9. The method of claim 8, wherein R1 is an optionally substituted C1-6 alkyl.
10. The method of claim 9, wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted.
11. The method of claim 1, wherein R1 is an optionally substituted cycloaliphatic.
12. The method of claim 11, wherein R1 is an optionally substituted monocyclic cycloaliphatic or an optionally substituted bicyclic cycloaliphatic.
13. The method of claim 12, wherein R1 is an optionally substituted 3-9 membered monocyclic cycloaliphatic.
14. The method of claim 13, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with halo, hydroxy, aliphatic, amino, carboxy, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl.
15. The method of claim 12, wherein R1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic.
16. method of claim 15, wherein R1 is an optionally substituted 7-10 membered bicyclic cycloalkyl or an optionally substituted 7-10 membered bicyclic cycloalkenyl.
17. The method of claim 16, wherein R1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, and bicyclo[2.2.2]oct-2-ene-yl.
18. The method of claim 1, wherein R1 is an optionally substituted monocyclic heterocycloaliphatic or an optionally substituted bicyclic heterocycloaliphatic.
19. The method of claim 18, wherein R1 is an optionally substituted 3-8 membered monocyclic heterocycloaliphatic having 1-3 heteroatoms independently selected from N, O, and S.
20. The method of claim 19, wherein R1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
21. The method of claim 18, wherein R1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms independently selected from N, O, and S.
22. The method of claim 21, wherein R1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic.
23. The method of claim 22, wherein R1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted.
24. The method of claim 1, wherein R1 is one selected from bicyclo[2.2.1]heptane-2-yl; bicyclo[2.2.1]hept-2-ene-5-ylmethyl; cycloheptane-yl; cyclohexylmethyl; N-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; neohexyl, cyclooctane-3-yl; cyclohexylmethyl; and 2-methylbutyl.
25. The method of claim 1, wherein each R2 is hydrogen or optionally substituted C1-6 aliphatic.
26. The method of claim 25, wherein each R2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
27. The method of claim 25, wherein each R2 is hydrogen.
28. The method of claim 1, wherein X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is independently a bond, or an independently and optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CONRB—, —CO2—, —NRBCO2—, —SO2—, —O—, or —NRBCO—; R6 is RB; and each RB is hydrogen or optionally substituted C1-3 aliphatic.
29. The method of claim 28, wherein X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C are hydrogen, or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
30. The method of claim 1, wherein X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is —CO—, —CONH—, —CO2—, —NHCO2—, —SO2—, —O—, or —NHCO—, and R6 is hydrogen or optionally substituted C1-3 aliphatic.
31. The method of claim 1, wherein X1 is —NR3A—, wherein R3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C are hydrogen or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
32. The method of claim 1, wherein X4 is —CR′4AR′4B—, wherein each of R′4A and R′4B are hydrogen.
33. The method of claim 1, wherein R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocycloaliphatic.
34. The method of claim 1, wherein m is 2 and n is 2.
35. The method of claim 1, wherein q is 0 or 4.
36. A method of modulating the activity of a muscarinic receptor comprising the step of contacting said receptor with a compound selected from
Figure US20080113958A1-20080515-C00056
Figure US20080113958A1-20080515-C00057
Figure US20080113958A1-20080515-C00058
Figure US20080113958A1-20080515-C00059
Figure US20080113958A1-20080515-C00060
Figure US20080113958A1-20080515-C00061
Figure US20080113958A1-20080515-C00062
37. A compound of formula I:
Figure US20080113958A1-20080515-C00063
a pharmaceutically acceptable salt thereof, wherein
X is —NR3A—;
X2 is —CR′3BR′3C—;
X3 is —CR4AR4B—;
X4 is —CR′4CR′4B—;
R1 is hydrogen, optionally substituted C1-12 aliphatic, optionally substituted cycloaliphatic, or optionally substituted heterocycloaliphatic;
Each R2 is independently -ZAR5, wherein each ZA is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, —P(O)(ORA)—, —P(O)(ORA)NRA— or —NRASO2NRA—,
Each R5 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RA is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R2 and R3A together with the atoms to which they are attached form an optionally substituted 4-10 membered heterocyclic,
Each of R3A, R′3B, and R′3C is independently -ZBR6, wherein each ZB is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, —P(O)(ORB)—, —P(O)(ORB)NRB— or —NRBSO2NRB—,
Each R6 is independently RB, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RB is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group, or
One of R3A or R′3B and R4A together with the atoms to which they are attached form an optionally substituted 3-10 membered cycloaliphatic or an optionally substituted 3-10 membered heterocycloaliphatic;
Each of R4A, R′4A, R4B, and R′4B is independently -ZCR7, wherein each ZC is independently a bond or is an optionally substituted C1-8 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, —P(O)(ORC)—, —P(O)(ORC)NRC— or —NRCSO2NRC—,
Each R7 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3,
Each RC is independently hydrogen, optionally substituted C1-6 aliphatic, optionally substituted cycloaliphatic, optionally substituted heterocycloaliphatic, optionally substituted aryl, or optionally substituted heteroaryl, or
R4A and R4B together with the carbon atom to which they are attached form a carbonyl group;
m is 1-3;
n is 1-3; and
q is 0-4.
38. The compound of claim 37, wherein X1 is —NR3A— and X2 is —CR′3AR′3B—.
39. The compound of claim 38, wherein X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein R3B and R3C together with the carbon atom to which they are attached form a carbonyl group.
40. The compound of claim 37, wherein X1 is —NR3A— and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C is hydrogen.
41. The compound of claim 37, wherein R1 is an optionally substituted C1-12 aliphatic.
42. The compound of claim 41, wherein R1 is an optionally substituted group selected from C1-12 alkyl, C1-12 alkenyl, or C1-12 alkynyl.
43. The compound of claim 42, wherein R1 is an optionally substituted C1-6 alkyl.
44. The compound of claim 43, wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, hexyl, 3,3-dimethylbutyl, or 3-methylbutyl, each of which is optionally substituted.
45. The compound of claim 37, wherein R1 is an optionally substituted cycloaliphatic.
46. The compound of claim 45, wherein R1 is an optionally substituted monocyclic cycloaliphatic or an optionally substituted bicyclic cycloaliphatic.
47. The compound of claim 46, wherein R1 is an optionally substituted 3-9 membered monocyclic cycloaliphatic.
48. The compound of claim 47, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with halo, hydroxy, aliphatic, amino, carboxy, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl.
49. The compound of claim 46, wherein R1 is an optionally substituted 7-10 membered bicyclic cycloaliphatic.
50. The compound of claim 49, wherein R1 is an optionally substituted 7-10 membered bicyclic cycloalkyl or an optionally substituted 7-10 membered bicyclic cycloalkenyl.
51. The compound of claim 50, wherein R1 is an optionally substituted group selected from bicyclo[2.1.1]hexane-yl, bicyclo[2.2.1]heptane-yl, bicyclo[2.2.2]octane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane-yl, or bicyclo[−3.3.1]nonane-yl, bicyclo[2.1.1]hex-2-ene-yl, bicyclo[2.2.1]hept-2-ene-yl, and bicyclo[2.2.2]oct-2-ene-yl.
52. The compound of claim 37, wherein R1 is an optionally substituted monocyclic heterocycloaliphatic or an optionally substituted bicyclic heterocycloaliphatic.
53. The compound of claim 52, wherein R1 is an optionally substituted 3-8 membered monocyclic heterocycloaliphatic having 1-3 heteroatoms independently selected from N, O, and S.
54. The compound of claim 53, wherein R1 is a tetrahydrofuran-yl, tetrahydro-2H-thiopyran-yl, pyrrolidine-yl, imidazolidine-yl, 1,4-dioxane-yl, morpholine-yl, piperidine-yl, piperazine-yl, tetrahydro-2H-pyran-yl, pyrazolidine-yl, or thiomorpholine-yl, each of which is optionally substituted with 1-3 of halo, amido, acyl, (heterocycloaliphatic)carbonyl, alkenyloxycarbonyl or combinations thereof.
55. The compound of claim 52, wherein R1 is an optionally substituted 7-10 membered bicyclic heterocycloaliphatic having 1-2 heteroatoms independently selected from N, O, and S.
56. The compound of claim 55, wherein R1 is an optionally substituted 7-10 membered bridged bicyclic heterocycloaliphatic or an optionally substituted 7-10 membered fused bicyclic heterocycloaliphatic.
57. The compound of claim 56, wherein R1 is 8-azabicyclo[3.2.1]octane-yl, or azabicyclo[2.2.1]heptane-yl, each of which is optionally substituted.
58. The compound of claim 37, wherein R1 is one selected from bicyclo[2.2.1]heptane-2-yl; bicyclo[2.2.1]hept-2-ene-5-ylmethyl; cycloheptane-yl; cyclohexylmethyl; N-ethoxycarbonylpiperidine-4-yl; 8-ethoxycarbonyl-8-azabicyclo[3.2.1]octane-3-yl; neohexyl, cyclooctane-3-yl; cyclohexylmethyl; and 2-methylbutyl.
59. The compound of claim 37, wherein R2 is hydrogen or optionally substituted C1-6 aliphatic.
60. The compound of claim 59, wherein R2 is an optionally substituted methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, or combinations thereof, each of which is optionally substituted.
61. The compound of claim 37, wherein X1 is —NR3A—, wherein R3A is ZBR6, each ZB is independently a bond, or an independently and optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CONRB—, —CO2—, —NRBCO2—, —SO2—, —O—, or —NRBCO—, R6 is RB, and each RB is hydrogen or optionally substituted C1-3 aliphatic.
62. The compound of claim 37, wherein X2 is —CR′3BR′3C—, wherein R′3B and R′3C are each hydrogen, or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
63. The compound of claim 37, wherein X1 is —NR3A—, wherein R3A is -ZBR6, each ZB is —CO—, —CONH—, —CO2—, —NHCO2—, —SO2—, —O—, or —NHCO—, and R6 is hydrogen or optionally substituted C1-3 aliphatic.
64. The compound of claim 37, wherein X1 is —NR3A—, wherein R3A is one selected from hydrogen, aminocarbonyl, methyl, methylcarbonyl, and N,N-dimethylaminocarbonyl; and X2 is —CR′3BR′3C—, wherein each of R′3B and R′3C are hydrogen or R′3B and R′3C together with the carbon atom to which they are attached form a carbonyl group.
65. The compound of claim 37, wherein X4 is —CR′4AR′4B—, wherein each of R′4A and R′4B are hydrogen.
66. The compound of claim 37, wherein m is 2 and n is 2.
67. The compound of claim 37, wherein q is 0 or 4.
68. A compound selected from
Figure US20080113958A1-20080515-C00064
Figure US20080113958A1-20080515-C00065
Figure US20080113958A1-20080515-C00066
Figure US20080113958A1-20080515-C00067
Figure US20080113958A1-20080515-C00068
Figure US20080113958A1-20080515-C00069
Figure US20080113958A1-20080515-C00070
Figure US20080113958A1-20080515-C00071
Figure US20080113958A1-20080515-C00072
Figure US20080113958A1-20080515-C00073
69. A method of treating or reducing the severity of a muscarinic receptor mediated disease in a mammal, comprising the step of administering to said mammal a compound as described in claim 37.
70. The method of claim 69, wherein said muscarinic receptor is M4.
71. The method of claim 69, wherein said muscarinic receptor is M1.
72. A method of treating or reducing the severity of a disease in a patient, wherein said disease is selected from CNS derived pathologies including cognitive disorders, Attention Deficit Hyperactivity Disorder (ADHD), obesity, Alzheimer's disease, various dementias such as vascular dementia, psychosis associated with CNS disorders including schizophrenia, mania, bipolar disorders, pain conditions including acute and chronic syndromes, Huntington's Chorea, Friederich's ataxia, Gilles de la Tourette's Syndrome, Downs Syndrome, Pick disease, clinical depression, Parkinson's disease, peripheral disorders such as reduction of intra ocular pressure in Glaucoma and treatment of dry eyes and dry mouth including Sjögren's Syndrome, bradycardia, gastric acid secretion, asthma, GI disturbances, and wound healing, wherein said method comprises the step of contacting said patient with a compound as described in claim 37.
73. A pharmaceutical composition comprising a compound according to claim 37 and a pharmaceutical carrier.
US11/894,092 2006-08-18 2007-08-20 Modulators of muscarinic receptors Expired - Fee Related US7786107B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/894,092 US7786107B2 (en) 2006-08-18 2007-08-20 Modulators of muscarinic receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83870106P 2006-08-18 2006-08-18
US11/894,092 US7786107B2 (en) 2006-08-18 2007-08-20 Modulators of muscarinic receptors

Publications (3)

Publication Number Publication Date
US20080113958A1 true US20080113958A1 (en) 2008-05-15
US20100063021A9 US20100063021A9 (en) 2010-03-11
US7786107B2 US7786107B2 (en) 2010-08-31

Family

ID=38972969

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/894,092 Expired - Fee Related US7786107B2 (en) 2006-08-18 2007-08-20 Modulators of muscarinic receptors

Country Status (7)

Country Link
US (1) US7786107B2 (en)
EP (1) EP2051715A2 (en)
JP (1) JP2010501561A (en)
CN (1) CN101573121A (en)
AU (1) AU2007284350A1 (en)
CA (1) CA2660974A1 (en)
WO (1) WO2008021545A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063288A1 (en) * 2017-05-12 2018-11-15 Mavalon Therapeutics Limited Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors

Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654287A (en) * 1970-08-26 1972-04-04 Mead Johnson & Co Spiroindanylpiperidines
US3666764A (en) * 1970-08-26 1972-05-30 Mead Johnson & Co Spiroindenylpiperidines
US3959475A (en) * 1973-12-12 1976-05-25 American Hoechst Corporation Substituted 1,3-dihydrospiro(isobenzofuran)s
US3962259A (en) * 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
US4233307A (en) * 1978-02-13 1980-11-11 Sumitomo Chemical Company, Limited Spiro-4'-piperidine compounds and their pharmaceutical compositions
US4349549A (en) * 1981-05-18 1982-09-14 Syntex (U.S.A.) Inc. Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s
US4558049A (en) * 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US4612121A (en) * 1983-06-08 1986-09-16 Chromtech Ab Separation material, methods of producing a separation material and use of orosomucoid, functional analogs thereto or derivatives or fragments thereof for separation purposes
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
US5219860A (en) * 1990-03-05 1993-06-15 Merck Sharp & Dohme Limited Spirocyclic antipsychotic agents
US5457207A (en) * 1993-10-05 1995-10-10 Regents Of The University Of Minnesota Spirovesamicols
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5652235A (en) * 1992-12-11 1997-07-29 Merck & Co., Inc. Method of using spiro piperidines to promote the release of growth hormone
US5658921A (en) * 1992-06-12 1997-08-19 H. Lundbeck A/S Dimeric piperidine, tetrahydropyridine and piperazine derivatives
US5665725A (en) * 1991-06-13 1997-09-09 H. Lundbeck Piperidine derivatives having anxiolytic effect
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5885999A (en) * 1996-01-29 1999-03-23 Merck Sharp & Dohme Ltd. Serine derivatives and their use as therapeutic agents
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US6166040A (en) * 1998-05-13 2000-12-26 Eli Lilly And Company Limited Indole compounds
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6316437B1 (en) * 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6326375B1 (en) * 1999-08-20 2001-12-04 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6436962B1 (en) * 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6566367B2 (en) * 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
US6713487B2 (en) * 2001-03-02 2004-03-30 Bristol-Myers Squibb Co. Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US6828440B2 (en) * 2001-04-18 2004-12-07 Euro-Celtique, S.A. Spiroindene and spiroindane compounds
US6869960B2 (en) * 2002-01-28 2005-03-22 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US7205417B2 (en) * 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1575800A (en) 1978-05-16 1980-10-01 Sumitomo Chemical Co Spiro amines their production and compositions containing them
JPS5815979A (en) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative and its preparation
JPS5959685A (en) 1982-09-28 1984-04-05 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative and its preparation
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
CA2037357A1 (en) 1990-03-02 1991-09-03 Ben E. Evans Methods for using spirocyclic oxytocin antagonists
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EP0813414A4 (en) 1993-10-19 1999-07-21 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
WO1995014025A1 (en) 1993-11-16 1995-05-26 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
WO1995028389A1 (en) 1994-04-15 1995-10-26 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997041878A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
CA2253390A1 (en) 1996-05-07 1997-11-13 Merck & Co., Inc. Enhancement of sleep with a growth hormone secretagogue
ATE327245T1 (en) 1997-07-31 2006-06-15 Elan Pharm Inc COMPOUNDS CONTAINING A 4-AMINO-PHENYLALANINE GROUP WHICH INHIBIT VLA-4-MEDIATED ADHESION OF LEUKOCYTES
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
ID29137A (en) 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
JP2002521441A (en) 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Propenamide as a CCR5 modulator
CA2338764A1 (en) 1998-07-28 2000-02-10 Thomas W. Ku Substituted anilide compounds and methods
CA2356269A1 (en) 1998-12-24 2000-07-06 Yoshihisa Akiyama Pain control agent
ITMI991452A1 (en) 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl SELECTIVE ANTAGONISTS FOR M2 RECEPTORS WITH STRUCTURE 5H-DIBENZO B, FAZEPINICA
US6803372B2 (en) 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
WO2001022919A2 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof
WO2001029027A1 (en) 1999-10-22 2001-04-26 Sankyo Company, Limited 2-alkoxybenzene derivatives
AU2274101A (en) 1999-12-21 2001-07-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001064213A1 (en) 2000-03-02 2001-09-07 Smithkline Beecham Corporation Compounds and methods
JP2001278886A (en) 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd Benzoxazine derivative and medicament containing the same
JP2002316987A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Medicine including 2-alkoxybenzene derivative
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
UA77814C2 (en) 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
PT2208727E (en) 2002-09-19 2012-10-11 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
US7365079B2 (en) 2002-11-29 2008-04-29 Banyu Pharmaceutical Co., Ltd. Azole derivatives
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
SE0300458D0 (en) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
CA2519220A1 (en) 2003-03-18 2004-09-30 Merck & Co., Inc. Amino cyclobutylamide modulators of chemokine receptor activity
CA2520114A1 (en) 2003-04-04 2004-10-21 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
CN1297557C (en) 2003-04-10 2007-01-31 上海药明康德新药开发有限公司 Preparation of spirocyclic template compound
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
CA2550735A1 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CA2546147A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
RU2006132465A (en) 2004-02-10 2008-03-20 Ф.Хоффманн-Ля Рош Аг (Ch) CCR5 CHEMOKIN RECEPTOR MODULATORS
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
CA2561801A1 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
EP1753429A1 (en) 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
CN101031296A (en) * 2004-08-19 2007-09-05 弗特克斯药品有限公司 Modulators of muscarinic receptors
CN101056861B (en) 2004-09-07 2011-04-06 万有制药株式会社 Carbamoyl-substituted spiro derivative
NZ555444A (en) * 2004-11-29 2011-01-28 Vertex Pharma Modulators of muscarinic receptors

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666764A (en) * 1970-08-26 1972-05-30 Mead Johnson & Co Spiroindenylpiperidines
US3654287A (en) * 1970-08-26 1972-04-04 Mead Johnson & Co Spiroindanylpiperidines
US3959475A (en) * 1973-12-12 1976-05-25 American Hoechst Corporation Substituted 1,3-dihydrospiro(isobenzofuran)s
US3962259A (en) * 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
US4233307A (en) * 1978-02-13 1980-11-11 Sumitomo Chemical Company, Limited Spiro-4'-piperidine compounds and their pharmaceutical compositions
US4349549A (en) * 1981-05-18 1982-09-14 Syntex (U.S.A.) Inc. Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s
US4558049A (en) * 1982-11-24 1985-12-10 Farmitalia Carlo Erba S.P.A. Antipsycotic benzoxazines
US4612121A (en) * 1983-06-08 1986-09-16 Chromtech Ab Separation material, methods of producing a separation material and use of orosomucoid, functional analogs thereto or derivatives or fragments thereof for separation purposes
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
US5219860A (en) * 1990-03-05 1993-06-15 Merck Sharp & Dohme Limited Spirocyclic antipsychotic agents
US5324733A (en) * 1990-03-05 1994-06-28 Merck Sharpe & Dohme Ltd. Spirocyclic antipsychotic agents
US5665725A (en) * 1991-06-13 1997-09-09 H. Lundbeck Piperidine derivatives having anxiolytic effect
US5693643A (en) * 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5658921A (en) * 1992-06-12 1997-08-19 H. Lundbeck A/S Dimeric piperidine, tetrahydropyridine and piperazine derivatives
US5536716A (en) * 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5652235A (en) * 1992-12-11 1997-07-29 Merck & Co., Inc. Method of using spiro piperidines to promote the release of growth hormone
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5457207A (en) * 1993-10-05 1995-10-10 Regents Of The University Of Minnesota Spirovesamicols
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) * 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US5885999A (en) * 1996-01-29 1999-03-23 Merck Sharp & Dohme Ltd. Serine derivatives and their use as therapeutic agents
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6166040A (en) * 1998-05-13 2000-12-26 Eli Lilly And Company Limited Indole compounds
US6294534B1 (en) * 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6326375B1 (en) * 1999-08-20 2001-12-04 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6316437B1 (en) * 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6436962B1 (en) * 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US6566367B2 (en) * 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
US6943199B2 (en) * 2000-12-12 2005-09-13 Neurogen Corporation Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
US6713487B2 (en) * 2001-03-02 2004-03-30 Bristol-Myers Squibb Co. Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6828440B2 (en) * 2001-04-18 2004-12-07 Euro-Celtique, S.A. Spiroindene and spiroindane compounds
US7205417B2 (en) * 2001-08-07 2007-04-17 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6869960B2 (en) * 2002-01-28 2005-03-22 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives

Also Published As

Publication number Publication date
EP2051715A2 (en) 2009-04-29
WO2008021545A2 (en) 2008-02-21
US20100063021A9 (en) 2010-03-11
CA2660974A1 (en) 2008-02-21
CN101573121A (en) 2009-11-04
WO2008021545A3 (en) 2008-04-03
AU2007284350A1 (en) 2008-02-21
JP2010501561A (en) 2010-01-21
US7786107B2 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
US7786308B2 (en) Muscarinic modulators
US7786141B2 (en) Dihydrospiroindene modulators of muscarinic receptors
US8263605B2 (en) Modulators of muscarinic receptors
US8304423B2 (en) Modulators of muscarinic receptors
US7696201B2 (en) Modulators of muscarinic receptors
US7858790B2 (en) Modulators of muscarinic receptors
US7786107B2 (en) Modulators of muscarinic receptors
US7973162B2 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIES, ROBERT J.;XU, JINWANG;REEL/FRAME:020366/0606

Effective date: 20080111

Owner name: VERTEX PHARMACEUTICALS INCORPORATED,MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAVIES, ROBERT J.;XU, JINWANG;REEL/FRAME:020366/0606

Effective date: 20080111

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: MACQUARIE US TRADING LLC, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNORS:VERTEX PHARMACEUTICALS INCORPORATED;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC;REEL/FRAME:033292/0311

Effective date: 20140709

AS Assignment

Owner name: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001

Effective date: 20161013

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001

Effective date: 20161013

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180831